ueec_10q.htm

0001477932-19-004823.txt : 20190814 0001477932-19-004823.hdr.sgml : 20190814 20190814163147 ACCESSION NUMBER: 0001477932-19-004823 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190814 DATE AS OF CHANGE: 20190814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: United Health Products, Inc. CENTRAL INDEX KEY: 0001096938 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 841517723 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27781 FILM NUMBER: 191026947 BUSINESS ADDRESS: STREET 1: 10624 S. EASTERN AVE STREET 2: STE. A209 CITY: HENDERSON STATE: NV ZIP: 89052 BUSINESS PHONE: (877) 358-3444 MAIL ADDRESS: STREET 1: 10624 S. EASTERN AVE STREET 2: STE. A209 CITY: HENDERSON STATE: NV ZIP: 89052 FORMER COMPANY: FORMER CONFORMED NAME: United EcoEnergy Corp. DATE OF NAME CHANGE: 20060224 FORMER COMPANY: FORMER CONFORMED NAME: MNS EAGLE EQUITY GROUP III INC DATE OF NAME CHANGE: 19991019 10-Q 1 ueec_10q.htm FORM 10-Q ueec_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number: 000-27781

UNITED HEALTH PRODUCTS, INC.

(Exact name of Company as specified in its charter)

Nevada		84-1517723
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

10624 S. Eastern Ave., Suite A209

Henderson, NV

89052

(Address of Company's principal executive offices)

(Zip Code)

(877) 358-3444

(Company's telephone number, including area code)

None

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
N/A		N/A		N/A

Securities registered pursuant to Section 12(g) of the Act: Common stock, $.001 par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 the Securities Act. Yes ¨ No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by checkmark whether the registrant has submitted electronically on its corporate website, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the 12 preceding months (or such shorter period that the registrant was required to submit such file). Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x
		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares issued of the Registrant's Common Stock, as of August 13, 2019 was 176,588,907 issued and outstanding.

UNITED HEALTH PRODUCTS, INC.

FORM 10-Q QUARTERLY REPORT

TABLE OF CONTENTS

		PAGE
PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)

	Condensed Balance Sheets as of June 30, 2019 and December 31, 2018 (unaudited)		3

	Condensed Statements of Operations for the Three and Six Months Ended June 30, 2019 and June 30, 2018 (unaudited)		4

	Condensed Statement of Stockholders’ Deficiency for the Three and Six Months Ended June 30, 2019 and June 30, 2018 (unaudited)		5

	Condensed Statements of Cash Flows for the Six Months Ended June 30, 2019 and June 30, 2018 (unaudited)		7

	Notes to Condensed Financial Statements (unaudited)		8

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations		13

Item 3.	Quantitative and Qualitative Disclosures		19

Item 4.	Controls and Procedures		19

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings		20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		20

Item 3.	Defaults Upon Senior Securities		20

Item 4.	Mine Safety Disclosures		20

Item 5.	Other Information		20

Item 6.	Exhibits and Reports on Form 8-K		21

SIGNATURES			22

UNITED HEALTH PRODUCTS, INC.

Condensed Balance Sheets

(Unaudited)

	June 30,			December 31,
	2019			2018
ASSETS
Current Assets
Cash and Cash Equivalents	$	500,895		$	31,273
Accounts Receivable		36,019			11,010
Inventory		99,807			83,694
Total current assets		636,721			125,977

TOTAL ASSETS	$	636,721		$	125,977

Current Liabilities
Accounts payable and accrued expenses	$	235,214		$	243,713
Liability for unissued shares		201,843			201,843
Accrued liabilities - related parties		55,121			25,000
Notes payable – related parties		-			8,121
Total current liabilities		492,178			478,677

Commitments and Contingencies

Stockholders' Equity (Deficiency)
Common Stock - $.001 par value, 300,000,000 Shares
Authorized, 176,588,907 and 185,943,138 shares issued at June 30, 2019 and December 31, 2018, respectively and 176,588,907 and 171,793,138 shares outstanding at June 30, 2019 and December 31, 2018, respectively		176,589			185,943
Additional Paid-In Capital		23,403,837			19,198,343
Accumulated Deficit		(23,435,883	)		(19,736,986	)
Total Stockholders' Equity (Deficiency)		144,543			(352,700	)

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)	$	636,721		$	125,977

See notes to unaudited condensed financial statements.

3

Table of Contents

UNITED HEALTH PRODUCTS, INC.

Condensed Statements of Operations

(Unaudited)

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2019			2018			2019			2018

Revenues	$	25,009		$	1,851		$	25,009		$	31,778

Cost of goods sold		9,887			1,791			9,887			10,667

Gross profit		15,122			60			15,122			21,111

Operating Costs and Expenses
Selling, general and administrative expenses		356,369			918,491			3,314,861			1,297,083
Research and development		214,863			-			242,268			-
Total Operating Expenses		571,232			918,491			3,557,129			1,297,083

Loss from Operations		(556,110	)		(918,431	)		(3,542,007	)		(1,275,972	)

Other Income (Expenses)
Interest Expense		(156,890	)		-			(156,890	)		-
Other Income		-			3,886			-			3,886
Loss on debt settlement		-			-			-			(3,632,500	)

Total other income (expenses)		(156,890	)		3,886			(156,890	)		(3,628,614	)

Net Loss	$	(713,000	)	$	(914,545	)	$	(3,698,897	)		(4,904,586	)

Net Loss per common share:
Basic and diluted	$	(0.00	)	$	(0.01	)	$	(0.02	)		(0.03	)

Weighted average number of shares outstanding		175,270,956			169,787,931			173,730,328			168,984,736

See notes to unaudited condensed financial statements.

4

Table of Contents

UNITED HEALTH PRODUCTS, INC

Condensed Statement of Stockholders' Deficiency

Three and Six Months Ended June 30, 2018

(Unaudited)

Additional

Common Stock

Paid-in

Accumulated

Shares

Amount

Capital

Deficit

Total

Balance at December 31, 2017

164,969,663

$ 164,969

$ 13,304,617

$ (13,730,851 )

$ (261,265 )

Issuance of shares for notes payable and accrued interest

3,500,000

3,500

3,811,500

-

3,815,000

Issuance of common stock for services

50,000

50

54,450

-

54,500

Sale of common stock

440,725

441

275,660

-

276,101

Shares issued for liability of unissued shares

62,500

63

4,937

-

5,000

Shares held in escrow

14,150,000

14,150

(14,150 )

-

-

Net Loss

-

-

-

(3,990,041 )

(3,990,041 )

Balance at March 31, 2018

183,172,888

$ 183,173

$ 17,437,014

$ (17,720,892 )

$ (100,705 )

Issuance of common stock for services

800,000

800

619,200

-

620,000

Sale of common stock

698,697

699

481,401

-

482,100

Shares issued for liability of unissued shares

137,059

137

91,863

-

92,000

Net Loss

-

-

-

(914,545 )

(914,545 )

Balance at June 30, 2018

184,808,644

$ 184,809

$ 18,629,478

$ (18,635,437 )

$ 178,850

5

Table of Contents

UNITED HEALTH PRODUCTS, INC

Condensed Statement of Stockholders' Deficiency

Three and Six Months Ended June 30, 2019

(Unaudited)

Common Stock

Additional
Paid-in

Accumulated

Shares

Amount

Capital

Deficit

Total

Balance at December 31, 2018

185,943,138

$ 185,943

$ 19,198,343

$ (19,736,986 )

$ (352,700 )

Vesting of shares held in escrow

-

-

2,343,500

-

2,343,500

Issuance of common stock for services

400,000

400

379,600

-

380,000

Sale of common stock

150,000

150

74,850

-

75,000

Cancellation of escrow shares

(12,000,000 )

(12,000 )

12,000

-

-

Net Loss

-

-

-

(2,985,897 )

(2,985,897 )

Balance at March 31, 2019

174,493,138

$ 174,493

$ 22,008,293

$ (22,721,883 )

$ (540,097 )

Sale of common stock

1,685,769

1,686

1,034,064

-

1,035,750

Issuance of shares for notes payable and accrued liabilities – related party

410,000

410

204,590

-

205,000

Beneficial conversion feature

-

-

156,890

-

156,890

Net Loss

-

-

-

(713,000 )

(713,000 )

Balance at June 30, 2019

176,588,907

$ 176,589

$ 23,403,837

$ (23,435,883 )

$ 144,543

See notes to unaudited condensed financial statements.

6

Table of Contents

UNITED HEALTH PRODUCTS, INC.

Condensed Statements of Cash Flows

(Unaudited)

	For the Six Months Ended June 30,
	2019			2018

Cash Flows from Operating Activities:
Net (Loss)	$	(3,698,897	)	$	(4,904,586	)
Adjustments to Reconcile net (loss) to Net Cash Used In Operating Activities:
Stock based compensation		2,723,500			674,500
Loss on settlement of debt		-			3,632,500
Amortization of debt discount		156,890			-
Changes in assets and liabilities:
Accounts Receivable		(25,009	)		(5,641	)
Inventory		(16,113	)		6,216
Prepaid and other current assets		-			12,114
Accounts payable and accrued expenses		(8,499	)		(42,492	)
Accrued liabilities – related party		35,000			-
Net Cash Used In Operating Activities		(833,128	)		(627,389	)

Cash Flows from Investing Activities:		-			-

Cash Flows from Financing Activities:
Proceeds from related party		192,000			-
Repayments to related party		-			(78,500	)
Repayment on notes payable		-			(10,000	)
Proceeds from sale of common stock		1,110,750			855,201
Cash flow provided by financing activities		1,302,750			766,701
Increase in Cash and Cash Equivalents		469,622			139,312
Cash and Cash Equivalents – Beginning of period		31,273			189,942

CASH AND CASH EQUIVALENTS – END OF PERIOD	$	500,895		$	329,254

Supplemental cash flow information:
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

Non-cash Investing & Financing Activities:
Shares issued for debt and accrued interest	$	-		$	182,500
Shares issued related to liability for unissued shares	$	-		$	97,000
Shares issued and held in escrow	$	-		$	14,150
Share issued for notes payable and accrued liabilities – related party	$	205,000		$	-
Cancellation of shares	$	12,000		$	-

See notes to unaudited condensed financial statements.

7

Table of Contents

UNITED HEALTH PRODUCTS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE QUARTERS ENDED June 30, 2019 AND 2018

(unaudited)

Note 1. Organization and Basis of Preparation

United Health Products, Inc. ("United" or the "Company") is a product development and solutions company focusing its growth initiatives on the expanding wound-care industry and disposable medical supplies markets. The Company produces an innovative gauze product that absorbs exudate (fluids which have been discharged from blood vessels) by forming a gel-like substance upon contact.

Interim financial statements are prepared in accordance with GAAP for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Article 8 of Regulation S-X, as appropriate. In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of financial statements for the interim period, have been included.

These interim condensed financial statements should be read in conjunction with the Company's audited financial statements and notes for the period ended December 31, 2018 filed with the Securities and Exchange Commission on Form 10-K filed on April 1, 2019. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, as permitted by the SEC, although we believe the disclosures which are made are adequate to make the information presented not misleading.

Note 2. Significant Accounting Policies

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company's ability to continue as a going concern. The Company intends on financing its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Chief Executive Officer has agreed to advance funds or make payments of the Company's obligations at his discretion. There is no written agreement to continue this support.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.

8

Table of Contents

Trade Accounts Receivable and Concentration Risk

We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers which are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credits issued.

There was no provision for doubtful accounts recorded at June 30, 2019 and December 31, 2018. The Company recorded $0 and $0 in bad debt expense for the three and six month periods ended June 30, 2019 and 2018, respectively.

For the six months ended June 30, 2019, one customer made up 100% of the Company’s net revenue and three customers made up 94% of the Company’s outstanding accounts receivable balance.

For the six months ended June 30, 2018, two customers accounted for 62% and 24% of the Company’s net revenue, respectively.

For the year ended December 31, 2018, three customers made up 98.9% of the Company’s outstanding accounts receivable balance.

Inventory

Inventory is valued at the lower of cost or market using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of raw materials purchased by the Company and finished goods.

	June 30, 2019		December 31, 2018
Raw materials	$	72,121	$	46,121
Finished goods		27,686		37,573
	$	99,807	$	83,694

During the six months ended June 30, 2019 and 2018, the Company determined $0 and $0, respectively, of inventory should be impaired and written-off to cost of goods sold.

Stock Based Compensation

The Company issues restricted stock to consultants and employees for various services. Cost for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock for non-employees is measured at the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached and expense is recognized during the term at which the counterparty's performance is earned or at the date the shares are considered non-forfeitable. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services.

Per Share Information

Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the shares of common stock held in escrow. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred a net loss for the three and six months ended June 30, 2019 and 2018 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive.

The total potential common shares as of June 30, 2019 and 2018, include 50,100,000 of restricted stock units and 14,150,000 of common stock held in escrow, respectively.

9

Table of Contents

New Accounting Pronouncements, Recently Adopted Accounting Pronouncements

Leases

In February 2016, the FASB issued Accounting Standards Update (ASU) No. ASU 2016-02, Leases, which amends existing lease accounting guidance, including the requirement to recognize most lease arrangements on the balance sheet. The adoption of this standard will result in the Company recognizing a right-of-use asset representing its rights to use the underlying asset for the lease term with an offsetting lease liability. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has determined there is no impact to the financial statements as the Company does not have any lease agreements.

The Company considers all new pronouncements and management has determined that there have been no other recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

Note 3. Related Party Transactions

As of June 30, 2019 and December 31, 2018, notes payable to related parties totaled $0 and $8,121, respectively. These amounts are owed to Doug Beplate, our Chief Executive Officer. During the six months ended June 30, 2019, Mr. Beplate advanced the Company $192,000.

On April 22, 2019, the Company agreed to issue to Mr. Beplate convertible demand loans representing all outstanding cash loans made by Mr. Beplate to the Company. For any outstanding loans made on or before April 15, 2019, the loans are convertible at $0.50 per share and for all loans subsequent to April 15, 2019, the notes are convertible at $0.65 per share, in each case at the sole discretion of Mr. Beplate. The Company’s stock price on April 22, 2019 was $0.90 which resulted in a beneficial conversion feature of $156,890 which was recorded to interest expense.

During the six months ended June 30, 2019, Mr. Beplate converted $205,000 of notes payable and accrued liabilities at a conversion price of $0.50 into 410,000 shares of common stock. There is $0 remaining as unamortized debt discount.

During the year ended December 31, 2018, Mr. Beplate gave a personal vehicle to an employee of the Company valued at $30,000 in lieu of the Company paying travel expenses and consulting expenses. During 2018, the Company repaid a net amount of $305,207 of the outstanding notes payable balance from proceeds of private placements. These loans were for operating expenses of the Company, are due on demand and have no interest rate.

Per Mr. Beplate’s services agreement, he receives monthly compensation of $15,000 per month. During the year ended December 31, 2018, he received his entire salary of $180,000 and $61,500 of previously accrued compensation was paid, leaving a balance of $25,000. During the six months ended June 30, 2019, $35,000 of compensation was accrued and $4,879 was converted into stock as mentioned above, leaving a balance of $55,121.

The Company, by board resolution, approved an executive compensation stock bonus package for Mr. Beplate such that upon the sale of all or substantially all of the assets of the Company or other change in control or merger transaction in which the Company is involved, or in the event that no such transaction occurs by December 31, 2019, Mr. Beplate shall receive an amount equal to 15% post issuance of the then outstanding shares of the Company's common stock on a fully diluted basis. It was intended that the board approved stock bonus package will be in lieu of the 5% stock bonus that Mr. Beplate is already entitled to in the event of a sale of the Company’s assets or change in control or merger transaction per his services agreement. See “Note 4” regarding the granting of Restricted Stock Unit Agreements (“RSU’s”) to various officers, directors and consultants covering an aggregate of 50,100,000 shares of common stock to be issued upon the satisfaction of certain conditions described in Note 4. Included in the RSU’s are 33,000,000 to Douglas Beplate in lieu of the compensation stock bonus package described above.

During the six months ended June 30, 2019, the Company issued 100,000 shares of common stock to each of two directors for services rendered. The shares had a fair market value of $190,000.

10

Table of Contents

Note 4. Issuances of Securities

Share issuances 2018

During the six months ended June 30, 2018, the Company issued an aggregate of 19,838,931 shares of common stock. The Company issued 850,000 shares of common stock with a total fair market value of $674,500 for services, 1,276,481 shares of common stock were sold for total proceeds of $850,200, $5,000 of proceeds were received for 7,246 shares of common stock not yet issued and recorded as liability for unissued shares, 62,500 shares of common stock were issued related to $5,000 of previously recorded liability for unissued shares and 14,150,000 shares of common stock with a fair market value of $15,423,500 were issued and placed in escrow. The shares will be released from escrow upon the change of control of the Company. Management is unable to determine when a change of control will occur and $0 has been expensed as of June 30, 2018. The Company also issued 3,500,000 shares of common stock to convert $172,500 of notes payable and $10,000 of accrued interest. The shares were valued at their fair market value of $1.09 which resulted in a loss on debt settlement of $3,632,500.

Share issuances 2019

During the six months ended June 30, 2019, 1,435,769 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $910,750, 400,000 shares of common stock were sold to securities counsel for total cash proceeds of $200,000, 200,000 shares of common stock were issued to securities counsel for services rendered with a fair value of $190,000, 100,000 shares of common stock were issued to each of two directors for services rendered with a fair value of $190,000 and 410,000 shares of common stock were issued to the Company’s CEO for conversion of notes payable and accrued liabilities totaling $205,000. During the six months ended June 30, 2019, the following events occurred with respect to the aforementioned 14,150,000 shares held in escrow:

During the period ended June 30, 2019, the Company issued (i)1,600,000 shares to Nate Knight who is the Chief Financial Officer of the Company, 500,000 shares to the office administrator, who is a person affiliated with the Company’s CEO and 50,000 shares to a Technical Product Supervisor, who is the son of the office administrator which had been held in escrow and became vested by the Board of Directors for services provided. These shares had a fair market value of $1.09 per share at the date of issuance and $2,343,500 has been expensed during the six month period ended June 30, 2019.

The Company canceled 12,000,000 shares of the aforementioned 14,150,000 shares issued (which were not considered outstanding) in the first quarter of 2019 to various officers, directors and consultants.

Restricted stock units

The Board approved restricted stock unit agreements with its officers, directors and consultants covering an aggregate of 50,100,000 shares of common stock to be issued and delivered to such persons upon the earlier of (i) a change in control of the Company by a cash tender offer, merger, acquisition or otherwise or (ii) the Company achieving gross revenues of $20,000,000 in gross revenues on a go forward basis, or (iii) the commencement of an event by a third party without the Board’s approval to effect, or seek to effect, a change in control of the Company or the Company’s management. Restricted Stock Units for 12,000,000 shares were issued in replacement of the 12,000,000 shares that were canceled as described above.

			Weighted
			Average
			Grant
	Number of		Date Fair
	Units		Value
Total awards outstanding at December 31, 2018		-	$	-
Units granted		50,100,000	$	0.94
Units Exercised/Released		-	$	-
Units Cancelled/Forfeited		-	$	-
Total awards outstanding at June 30, 2019		50,100,000	$	0.94

Management is unable to determine when a change of control will occur and as of June 30, 2019, there was $47,094,000 of unrecognized compensation cost related to unvested restricted stock unit awards.

11

Table of Contents

Note 5. Litigation

There are no legal proceedings pending or threatened against us, except as follows:

During 2017, a Complaint was filed with the United States District Court, Southern District of New York by Steven Safran as Plaintiff against the Company and Douglas Beplate, its CEO, as Defendant. This court case was transferred to the United States District Court in Las Vegas, Nevada. Mr. Safran is seeking damages and monies allegedly owed pursuant to an employment agreement and allegedly unpaid loans of $245,824 provided to Defendants. The Company has denied Plaintiff’s allegations and intends to vigorously defend said lawsuit. The parties have held various depositions and the Company has a motion to dismiss which is pending with the court. No accrual has been recorded related to this litigation.

In July 2015, the Company entered into a consulting agreement retaining the services of Maxim Group LLC. An amended agreement was executed in January 2018. A total of 4 million shares of common stock were issued to Maxim in exchange for its obligation to perform certain advisory and other services. In the fourth quarter of 2018, the Company notified Maxim of its intent to file for arbitration pursuant to the consulting agreement. Maxim, without providing a similar notice to the Company, immediately filed a complaint with FINRA seeking release of a restrictive legend from a Company stock certificate in the amount of 500,000 shares. The Company filed an affirmative defense that the required notice of arbitration was not provided to the Company prior to filing. The Company also filed a counterclaim for breach of contract seeking restitution of the original 4 million shares issued to Maxim and the Company filed several counterclaims alleging material misrepresentations by Maxim to various entities. The Company intends to vigorously defend Maxim’s complaint and to pursue to its counterclaims. Currently, the Company and Maxim have a scheduled arbitration with FINRA which will be held in September 2019.

Philip Forman, who served in positions as Chairman, a director, Chief Executive Officer and Chief Medical Advisor at various time between 2011 and October 2015, has filed a lawsuit against the Company and our Chief Executive Officer, Douglas Beplate, in the United States District Court of the District of Nevada. The claimant is claiming, among other things, that: the June 25, 2015 Amendment to his November 10, 2014 Employment Agreement with the Company, which terminated the Employment Agreement on October 1, 2015, is not valid because of lack of consideration; that a July 22, 2015 Stock Purchase Agreement pursuant to which the claimant sold Company shares issued to him under the Amendment to a third a party is unenforceable (despite the fact that all payment for the shares under the Stock Purchase Agreement was made); that the plaintiff’s 2014 Employment Agreement is enforceable and that he is entitled to cash and stock compensation under that Employment Agreement (without giving regard to the Amendment); that if the Amendment is enforceable, he is entitled to the shares issued under the Amendment (without mention that those shares were sold to a third party under the Stock Purchase Agreement described above); and that the Company and Mr. Beplate defrauded the plaintiff relating to the foregoing. The plaintiff is seeking declaratory judgment regarding the parties’ relative rights under the Employment Agreement, the Amendment and the Stock Purchase Agreement; money damages of no less than $2,795,000; and punitive damages of $8,280,000. The Company believes that it has meritorious defenses to the matters claimed as well as counterclaims against the claimant. We plan to vigorously respond to the claims and pursue our remedies. We cannot predict the outcome with certainty.

In the Southern District of New York, FSR Inc. commenced a lawsuit in 2018 against Korsair Holdings A.G. seeking among other claims for relief, rescission of the transfer of 3,050,000 shares of United Health Products that FSR sold to Korsair in 2011. Third-Party Plaintiff, JEC Consulting Associates, LLC as Liquidator of LeadDog Capital L.P., Intervenor (“Intervenor”) in the above matter, filed a third-party complaint against United Health Products, and Douglas K. Beplate (“Beplate”) alleging among other things that the Company and Mr. Beplate refused to have the Rule 144 restrictive legend removed from the Korsair certificate held by JEC, and concomitantly fraudulently deprive JEC as Liquidator of LeadDog of the ability to sell the Shares in the open market, knowingly, intentionally and directly causing economic harm to LeadDog Capital L.P. Intervenor as Third Party Plaintiff further alleges that the Company and Mr. Beplate as Third-Party Defendants are not only monetarily liable to Third-Party Plaintiff for compensatory damages of $2,500,000 but should be made to pay exemplary damages in an amount determined by the Court, but not less than an equal amount - $2,500,000. Third-Party Plaintiff demands judgment for the above referenced amounts and for the Court to also declare that the 3,050,000 shares are free trading; that Third-Party Plaintiff’s rights to 2.5 million of the Shares are superior to the claims of Plaintiff FSR; that Plaintiff FSR has no claim to 2.5 million of the 3,050,000 Shares reflected by the Korsair certificate; that the Company and Mr. Beplate are to instruct its current transfer agent to remove the restrictive legend on the Korsair certificate for the Shares; and an order directing the Company and Mr. Beplate to instruct the Company’s transfer agent to exchange the Korsair certificate for new free-trading, unrestricted certificates. The Company believes that it had legal right to decline to instruct the transfer agent to remove the restrictive legend from the Korsair Shares where the ownership of the aforementioned shares have been in dispute and the Korsair shares have not been submitted for transfer to its transfer agent in proper form under the uniform commercial code.

Note 6. Liability for Unissued Shares

The Company has recognized a "Liability for unissued shares" for shares granted to employees and consultants along with shares purchased by investors, but unissued as of the balance sheet date. The granted shares are recorded at the fair market value of the shares to be issued at the grant date and a corresponding current liability is recorded for these unissued shares. The activity in this account and balances, classified as Liabilities for unissued shares, as of June 30, 2019 and December 31, 2018 was as follows:

	2019		2018
Balance, beginning	$	201,843	$	211,843
Issuance of shares in satisfaction of liability		-		(10,000	)
Balance, ending	$	201,843	$	201,843

The total number of shares granted but unissued were 2,414,059 and 2,414,059, as of June 30, 2019 and December 31, 2018, respectively.

Note 7. Subsequent Events

The Company has evaluated events subsequent to June 30, 2019, through the date whereupon the financial statements were issued and has determined that there are no material events that need to be disclosed.

12

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed financial statements and related notes appearing elsewhere in this quarterly report on Form 10-Q. This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. The actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited to, those set forth under 'Risk Factors' in our annual report on Form 10-K for the fiscal year ended December 31, 2018, filed with SEC on April 1, 2019.

Recent Developments

The following developments in the Company’s business have occurred since the beginning of 2018:

	·	In February 2018, the Company completed and submitted to the U.S. Food and Drug Administration (“FDA”) all materials relevant for the pre-market approval (“PMA”) for HemoStyp under the FDA’s new and innovative CtQ Pilot-Program as a Class III application for internal surgical procedures. The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body – as evidenced by years of prior product usage and studies – to be approved for Class III internal surgical use. The FDA reviewed UHP’s HemoStyp as one of the participants for the program.

	·	The Company’s 2” x 4” Trauma Gauze™ product has been selected as the feature component for a new Advanced Wound Care Kit for Dick’s Sporting Goods (NYSE DKS).The Hemostyp pouches have been included under the Field and Stream label and are available in their stores nationwide since February 2018.

	·	In January 2018, the Company’s distribution partner, Quantum Health Group, filed an application for Class III use in general internal surgical procedures with the Ministry of Food and Drug Safety (“MFDS”) in South Korea. The Ministry of Food and Drug Safety provides the vision of "Safe Food and Drug, Healthy People, Well-being Society" and making extensive efforts to safeguard consumers and promote the public health by ensuring the safety of all foods, drugs, cosmetics, herbal medicines, and medical devices. Quantum received a response requiring additional data and testing. The Company intends to respond to the request and complete our application.

·
In March 2018, the Company obtained Class III and CE mark approval for HemoStyp in the European Economic Area (EEA). The EEA comprises the 28 European Union members and certain other countries. Accordingly, HemoStyp was approved for use in internal surgical procedures in more than 30 countries. This approval expired in August of 2018 and a new application will be prepared in conjunction with the new CE standards for Class III following the expected FDA Class III approval. The EEA approval was granted following the provision of all required documentation to the relevant regulatory agencies. The CE marking– CE is an acronym for the French term "Conformité Européenne"– certifies that a product has met EEA health, safety, and environmental requirements, which ensure consumer safety. Manufacturers in the EEA and abroad must meet CE marking requirements where applicable to market their products in Europe. A manufacturer who has gone through the conformity assessment process may affix the CE mark to its product. With the CE marking, the product may be marketed throughout the EEA and certain other countries, with a combined population exceeding 517 million and a GDP greater than $17 trillion.

·
In July 2018, the Company announced that it has been accepted as a Walmart.com supplier and offers two HemoStyp wound care products for online retail sale. Hemostrips® Hemostatic Bandages and Boo-boo Strip Hemostatic Bandages.

·
On August 8, 2018, the Company announced that its protocol submission for human testing had been reviewed by the FDA in furtherance of our efforts to achieve Class III approval for the product in the U.S. This FDA review was provided to the Institutional Review Board (IRB) for protocol and hospital site approval. UHP started the human trial study in November. The IRB is a committee that is independent of the FDA, and that is formally designated to approve, monitor, and review biomedical and behavioral research involving humans. The purpose of the IRB is to assure that appropriate steps are taken to protect the rights and welfare of humans participating as subjects in a research study. The Company’s human trial protocol calls for the application of HemoStyp in abdominal, cardiovascular thoracic and vascular surgical procedures to control bleeding sites. Prior to finalizing its human trial protocol, we submitted a Q-Sub – a request for FDA review — to the FDA, in conjunction with its previously filed Class III PMA submission application.

13

Table of Contents

	·	The IRB approved HemoStyp human trial is a prospective, non-inferiority, multi-center, randomized, open-label trial to observe HemoStyp in the management of bleeding during surgery; and, to assess the efficacy and safety of HemoStyp as an adjunct for management of secondary hemostasis in an operative setting. Our independently developed protocol has established endpoints for bleeding control.

	·	We expect that the human trials will be the last step to clear in obtaining FDA PMA Class III approval for HemoStyp. We have recruited a team of leading surgeons to conduct the study, and our lead investigator has successfully conducted over 20 medical device studies. We aim to complete this final regulatory stage as part of our strategy to supply the domestic and international hemostasis surgical markets.

	·	On October 25, 2018, the Company announced that, in connection with the FDA PMA Class III approval process for HemoStyp, UHP has been contacted by several medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who had expressed an interest in the Company's products and business strategy. In response to these inbound contacts, and to maximize shareholder value, the Company's board of directors has determined to conduct a review of strategic alternatives, which include a potential sale of the Company, joint venture or other commercial partnership, or a standalone growth plan. To assist in this review, the Company has retained Société Générale to serve as financial advisor to the Company and it has retained the law firm of Ruskin Moscou Faltischek PC to assist in the strategic review. There can be no assurances that any specific transaction will occur as a result of the retention of these firms.

	·	In August 2019, the Company announced that it has successfully completed the surgeries for its Human Trial study “Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting” which finalizes human trial enrollment. The Company is compiling and presenting all study data and human surgical results to an independent firm that will certify all data and finalize the Company’s PMA submission for class III FDA approval.

	·	In August 2019, the Company also announced that it has filed a patent application covering methods of forming and using a hemostatic material, and more specifically, methods of forming and using a hemostatic hydrocolloid that is formed into a gel, foam or spray used to control bleeding and oozing from a variety of wounds. Upon approval of the new patent, this will allow for the HemoStyp hydrocolloid to act as a conduit to transfer other properties associated with the treatment of wounds within the hydrocolloid. This enables HemoStyp to be bundled as a suite of multiple products for surgical and wound care applications.

Our HemoStyp Gauze Products

HemoStyp Hemostatic Gauze is a collagen-like natural substance created from chemically treated cellulose. It is an effective hemostatic agent registered with the FDA to help control bleeding from open wounds and body cavities. The HemoStyp hemostatic material contains no chemical additives, thrombin or collagen, and is hypoallergenic. When the product comes in contact with blood it expands slightly and converts to an adhesive gel that subsequently dissolves into glucose and saline. Because of its purity and the fact that it simply degrades to non-toxic end products, HemoStyp does not cause significant delay in healing as do certain other hemostatic materials. Additional testing has shown HemoStyp to be 100% absorbable in 24 hours or less. Tests have also been conducted to demonstrate the effectiveness of HemoStyp in thoracic and abdominal procedures. The Company continues to test for the effectiveness and the IFU (Instructions for Use) for abdominal and thoracic procedures.

HemoStyp Hemostatic Gauze is a flexible cloth-like material that is applied by folding the gauze as needed to fit the size of the wound or incision, and then placing the gauze onto the bleeding tissue. In surgical situations, the product converts to a transparent gel with a neutral pH level that allows the surgeon to monitor the coagulation process and also avoids damage to the surrounding tissue. In first responder or other non-surgical situations, putting a bandage on top of the gauze is optional and, in many cases, unnecessary. Since EMS (Emergency Medical Services) work is pre-hospital, rinsing the gauze out with saline or water is not necessary, as a wound will be debrided and possibly reopened prior to suturing at the hospital.

Our hemostatic gauze product line includes various configurations which have been developed to address the specific needs of our market segments and our existing customers, including the U.S. military. Our HemoStyp gauze products are sold in different sizes for use in superficial trauma cases, as a dental gauze and as a nasal dressing, and in a range of formats for veterinary applications, among others uses. The Company's hemostatic gauze product line now includes the following products:

	·	Veterinary Market type Products;
	·	Dental gauze for oral surgery;
	·	Several formats of Trauma Gauze™ for battlefield trauma; Adhesive bandages for use by consumers on cuts and abrasions; and,
	·	Island dressings to support intravenous procedures such as kidney dialysis.

14

Table of Contents

Existing and Potential Target Markets

Our technology is marketed as HemoStyp Gauze but is also available to customers with customized private labeling. We are customer driven. We distribute both nationally and internationally. We are servicing (or intend to service) our customers through distributors, sales representatives, industry-specialized telephone support, and the Internet. Our current and potential customer base for our HemoStyp includes, without limitation:

	·	Hospitals and Surgery Centers for all Internal Surgical usage, post FDA Class III approval
	·	Hospitals, Clinics and Physicians – For external trauma
	·	EMS, Fire Departments and Other First Responders
	·	Public Safety, Police Departments and Military
	·	Correctional Facilities
	·	Schools, Universities and Day Care Facilities
	·	Nursing Homes and Assisted Living Environments
	·	Home Care Providers
	·	Dental offices
	·	Sports Medicine Providers
	·	Veterinarians
	·	Municipalities and Government Agencies and
	·	Occupational and Industrial Healthcare Professionals Consumers

Plan of Operation

We believe that the Class III surgical markets, both domestic and international, represent the most attractive market for our products due to the limited competition from other Class III approved ORC (Oxidized Regenerated Cellulose) products and the resulting premium pricing for hemostatic agents that can meet the demanding requirements of the human surgical environment. In addition, our preliminary tests lead us to believe that the HemoStyp technology can compete successfully against established market participants and allow us to gain market share. Given this assessment, we have devoted considerable resources in 2018 and 2019 and currently completing the FDA process to gain access to this market in the U.S.

In February 2018, the Company completed and submitted to the FDA all materials relevant for the pre-market approval (“PMA”) for HemoStyp as a Class III application for internal surgical procedures. The 2017 U.S. market for hemostatic products used in internal surgery procedures is estimated at in excess of US$7 billion, of which the market for ORC or similar mechanical hemostatic products is estimated to be US$3.38 billion. This market is expected to grow at 6.2% annually to reach $4.57 billion by 2023 (source: October 2018 Market Data Forecast).

In August 2019, the Company announced that it has successfully completed the surgeries for its Human Trial study Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting which finalizes human trial enrollment. The Company is compiling and presenting all study data and human surgical results to an independent firm that will certify all data and finalize the Company s PMA submission for class III FDA approval.

In anticipation of receiving Class III approval, our strategy is to devote resources and seek partnerships that allow us to penetrate this market along with the other markets to which the Company already has access. We are evaluating the best paths to rapidly grow our revenue and profits, which could include commercial partnerships and licensing agreement with established market participants, in addition or as an alternative to raising the necessary capital to establish and grow our own marketing and distribution capabilities. We will carefully evaluate the returns on investment in each addressable market to ensure the judicious deployment of our capital to create shareholder value.

15

Table of Contents

We believe that refocusing the Company to become a stronger, medical technology corporation with a patented technology will enhance the Company’s value and overall market strength and allows for revenue generation via organic growth. Nevertheless, we have engaged Société Générale as described under “Recent Developments” to advise the Company on potential strategic alternatives including the possible sale of the Company and/or its intellectual assets. In the event that a transaction is not completed on terms satisfactory to the Company, if at all, the Company would require substantial additional financing to execute an organic business development strategy addressing all of its intended markets.

Results of Operations

Three Months ended June 30, 2019 versus Three Months ended June 30, 2018

During the three months ended June 30, 2019 and 2018, the Company had $25,009 and $1,851 of revenues, respectively. The increase in revenues is due to the Company having one customer order product during the current year compared to minimal revenues in the comparable quarter of the prior year. The Company has changed its focus and a pivot of all the Company’s energy in making our technology and product more commercially viable, by attempting to obtain FDA class III approval for internal surgical purposes. This process requires 100% of the Company’s resources and energy so the focus was removed from sales and marketing and full attention was focused on the FDA process. The reason for this change is that the Company believes the greatest value to its shareholders would come from this FDA class III approval for general surgical use. The completion of the human trials is expected to allow the Company to foster interest from potential merger and acquisition candidates. Also, with the Company’s focus on an acquisition partner, the Company did not want to engage new distribution partners that may create conflicts with the new prospective acquisition companies and tie their hands from a revenue or branding perspective. However, we expect that if a merger and acquisition candidate is identified, current vendor and future relationships and all pending purchase orders will be handed to the acquiring company for its facilitation. No assurances can be given that the Company will complete a transaction with a merger candidate on terms satisfactory to us, if at all.

Total operating expenses for the three months ended June 30, 2019 and 2018 were $571,232 and $918,491, respectively. The decrease in operating expenses is due primarily to a decrease in consulting/professional fees offset by an increase in research and development expenses of $214,863. The decrease in consulting/professional fees is due to the Company issuing 800,000 shares of common stock for services valued at $620,000 to various medical advisors during the three months ended June 30, 2018 and during the three months ended June 30, 2019 the Company did not issue any stock for services. The increase in research and development expenses is due to the Company going through the process to obtain FDA class III approval during the current period and not having these expenses in the prior year.

Our net loss for the three months ended June 30, 2019 and 2018 was $713,000 and $914,545, respectively. The decrease in the net loss is due to the Company not issuing shares for services during the period compared to shares issued for services of $620,000 as mentioned above, offset by an increase in research and development expense of $214,863 and interest expense of $156,890 related to amortization of debt discount related to beneficial conversion feature on notes payable – related party.

16

Table of Contents

Six Months ended June 30, 2019 versus Six Months ended June 30, 2018

During the six months ended June 30, 2019 and 2018, the Company had $25,009 and $31,778 of revenues, respectively. The decrease in revenues is due to the Company changing its focus and pivot all the Company’s energy in making our technology and product more commercially viable, by attempting to obtain FDA class III approval for internal surgical purposes. This process requires 100% of the Company’s resources and energy so the focus was removed from sales and marketing and full attention was focused on the FDA process. The reason for this change is that the Company believes the greatest value to its shareholders would come from this FDA class III approval for general surgical use. The completion of the human trials is expected to allow the Company to foster interest from potential merger and acquisition candidates. Also, with the Company’s focus on an acquisition partner, the Company did not want to engage new distribution partners that may create conflicts with the new prospective acquisition companies and tie their hands from a revenue or branding perspective. However, we expect that if a merger and acquisition candidate is identified, current vendor and future relationships and all pending purchase orders will be handed to the acquiring company for its facilitation. No assurances can be given that the Company will complete a transaction with a merger candidate on terms satisfactory to us, if at all.

Total operating expenses for the six months ended June 30, 2019 and 2018 were $3,557,129 and $1,297,083, respectively. The increase in operating expenses is due primarily to an increase in consulting/professional fees and an increase in research and development expenses. The increase in consulting/professional fees is due to the Company issuing 400,000 shares of common stock for services valued at $380,000 and 2,150,000 shares of common stock valued at $2,343,500 vested during the six months ended June 30, 2019 compared to the Company issuing 850,000 shares of common stock valued at $674,500 to various medical advisors during the six month period ended June 30, 2018. The increase in research and development of $242,268 is due to the Company going through the process to obtain FDA class III approval during the current period and not having these expenses in the prior year.

Our net loss for the six months ended June 30, 2019 was $3,698,897 as compared to net loss of $4,904,586 for the comparable period of the prior year. The decrease in the net loss is due to the Company having an increase in operating expenses of $2,260,046 as explained above, an increase of $242,268 in research and development expenses along with an increase of $156,890 of interest expense related to amortization of debt discount related to beneficial conversion feature on notes payable – related party offset by a decrease of $3,632,500 in loss on settlement of debt.

Financial Condition, Liquidity and Capital Resources

As of June 30, 2019, the Company had working capital of $144,543 and stockholders' equity of $144,543. The Company has not as yet attained a level of operations which allows it to meet its current overhead and may not attain profitable operations within the next few business operating cycles, nor is there any assurance that such an operating level can ever be achieved. The report of our independent registered public accounting firm on our 2018 financial statements includes a reference to going concern which indicated substantial doubt about our ability to continue as a going concern. While the Company has in the past funded its initial operations with private placements, and loans from related parties, there can be no assurance that adequate financing will continue to be available to the Company and, if available, on terms that are favorable to the Company. Our ability to continue as a going concern is also dependent on many events outside of our direct control, including, among other things, our ability to achieve our business goals and objectives, as well as improvement in the economic climate.

Cash Flows

The Company's cash on hand at June 30, 2019 and December 31, 2018 was $500,895 and $31,273, respectively.

Net cash used in operating activities for the six months ended June 30, 2019 was $833,128. The Company had net loss of $3,698,897 offset by stock issued for services of $2,723,500 and amortization of debt discount of $156,890. The Company also had an increase in accounts receivable of $25,009, an increase in inventory of $16,113, a decrease in accounts payable and accrued expenses of $8,499 and an increase in accrued liabilities – related party of $35,000. Net cash provided by financing activities was $1,302,750. This was due to the Company receiving $1,110,750 in proceeds from the sale of stock and receiving $192,000 from related party advances.

17

Table of Contents

Net cash used in operating activities for the six months ended June 30, 2018 was $627,389. The Company had net loss of $4,904,586 offset by stock issued for services of $674,500 and loss on settlement of debt of $3,632,500. The Company also had an increase in accounts receivable of $5,641, a decrease in inventory of $6,216, a decrease in prepaids and other current assets of $12,114 and a decrease in accounts payable and accrued expenses of $42,492. Net cash provided by financing activities was $766,701. This was due to the Company receiving $855,201 in proceeds from the sale of stock and repaying $78,500 in related party advances and $10,000 in notes payable.

Off-Balance Sheet Arrangements

As of June 30, 2019, we have no off-balance sheet arrangements.

Critical Accounting Policies

The preparation of financial statements and related disclosures in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following items as critical accounting policies.

Revenue Recognition

The Company recognizes revenues in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of its HemoStyp product by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

Stock Based Compensation

18

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company is in the process of implementing disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the ''Exchange Act''), that are designed to ensure that information required to be disclosed in the Company's Exchange Act reports are recorded, processed, summarized, and reported within the time periods specified in rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our Chief Executive Officer to allow timely decisions regarding required disclosure.

As of June 30, 2019, the Chief Executive Officer and Chief Financial Officer carried out an assessment of the effectiveness of the design and operation of our disclosure controls and procedure and concluded that the Company's disclosure controls and procedures were not effective as of June 30, 2019, because of the material weakness described below.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.

The material weakness identified during management's assessment was the lack of sufficient resources with SEC, generally accepted accounting principles (GAAP) and tax accounting expertise. This control deficiency did not result in adjustments to the Company's interim financial statements. However, this control deficiency could result in a material misstatement of significant accounts or disclosures that would result in a material misstatement to the Company's interim or annual financial statements that would not be prevented or detected. Accordingly, management has determined that this control deficiency constitutes a material weakness.

The Chief Executive Officer and Chief Financial Officer performed additional accounting and financial analyses and other post-closing procedures including detailed validation work with regard to balance sheet account balances, additional analysis on income statement amounts and managerial review of all significant account balances and disclosures in the Quarterly Report on Form 10-Q, to ensure that the Company's Quarterly Report and the financial statements forming part thereof are in accordance with accounting principles generally accepted in the United States of America. Accordingly, management believes that the financial statements included in this Quarterly Report fairly present, in all material respects, the Company's financial condition, results of operations, and cash flows for the periods presented.

Changes in Internal Control over Financial Reporting

During the three months ended June 30, 2019, there were no changes in our system of internal controls over financial reporting.

19

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

See “Note 5” in the Notes to Condensed Financial Statements.

Item 1A. Risk Factors

Not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a) From January 1, 2019 through June 30, 2019, we had no sales or issuances of unregistered common stock, except we made sales or issuances of unregistered securities listed in the table below:

Date of Sale

Title of Security

Number Sold

Consideration Received and Description of Underwriting or Other Discounts to Market Price or Convertible Security, Afforded to Purchasers

Exemption from Registration Claimed

If Option, Warrant or Convertible Security, terms of exercise or conversion

Jan. – March 31, 2019

Common Stock

550,000

$75,000 in cash, $380,000 in services rendered, no commissions paid

Rule 506;

Section 4(2)

Not applicable

April – June 30, 2019

Common Stock

2,095,769

$1,035,750 in cash, $205,00 conversion of notes payable and accrued liabilities

Rule 506;

Section 4(2)

Convertible at $0.50/share

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

20

Table of Contents

Item 6. Exhibits

The following exhibits are filed with this report, or incorporated by reference as noted:

3(i)		Articles of Incorporation of the Company dated February 28, 1997. (1)

3(ii)		Amendment to Articles of Incorporation. (1)

3(iii)		By-laws of the Company. (2)

3(iv)		August 2015 Amendment to Articles of Incorporation. (3)

10.1		Services Agreement with Louis Schiliro (5)

10.2		Services Agreement – Nate Knight (4)

10.3		January 2015 Services Agreement with Douglas Beplate (6)

10.4		Restricted Stock Unit Agreement - Louis Schiliro (8)

10.5		Restricted Stock Unit Agreement - Douglas Beplate (8)

21		Subsidiaries of the Registrant – none

31.1		Certification of Principal Executive Officer*

31.2		Certification of Principal Financial Officer*

32.1		Section 1350 Certificate by Principal Executive Officer*

32.2		Section 1350 Certificate by Principal Financial Officer*

99.1		2013 Employee Benefit and Consulting Services Compensation Plan (7)

101.SCH		Document, XBRL Taxonomy Extension (*)

101.CAL		Calculation Linkbase, XBRL Taxonomy Extension Definition (*)

101.DEF		Linkbase, XBRL Taxonomy Extension Labels (*)

101.LAB		Linkbase, XBRL Taxonomy Extension (*)

101.PRE		Presentation Linkbase (*)

___________

* Filed herewith.

(1)	Incorporated by reference to the Company's Form 10-Q for the quarter ended September 30, 2014.

(2)	Incorporated by reference to the Company's Form 10-K for the year ended December 31, 2005.

(3)	Incorporated by reference to Form 8-K dated August 7, 2015 – date of earliest event filed on August 10, 2015.

(4)	Incorporated by reference to Form 8-K dated November 23, 2014.

(5)	Incorporated by reference to the Company's Form 10-Q for the quarter ended June 30, 2018.

(6)	Incorporated by reference to the Form 8-K dated January 16, 2015.

(7) (8)	Incorporated by reference to Form 10-Q for the quarter ended June 30, 2015. Incorporated by reference to form 10-K for the fiscal year ended December 31, 2018.

21

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this amended report to be signed on its behalf by the undersigned, thereunto duly authorized on August 14, 2019.

	United Health Products, Inc.

	By:	/s/ Douglas Beplate
		Douglas Beplate Principal Executive Officer

	By:	/s/ Nate Knight
		Nate Knight
		Principal Financial Officer

EX-31.1 2 ueec_ex311.htm CERTIFICATION ueec_ex311.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Douglas Beplate certifies that:

1.	I have reviewed this quarterly report on Form 10-Q of United Health Products, Inc.;

2	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: August 14, 2019	By:	/s/ Douglas Beplate
		Douglas Beplate
		Principal Executive Officer

EX-31.2 3 ueec_ex312.htm CERTIFICATION ueec_ex312.htm

EXHIBIT 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Nate Knight certifies that:

1.	I have reviewed this quarterly report on Form 10-Q of United Health Products, Inc.;

2	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: August 14, 2019	By	/s/ Nate Knight
		Nate Knight
		Principal Financial Officer

EX-32.1 4 ueec_ex321.htm CERTIFICATION ueec_ex321.htm

EXHIBIT 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), Douglas Beplate, Principal Executive Officer of United Health Products, Inc. (the "Company") of the Company, hereby certifies that, to the best of his knowledge:

	1.	The Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, to which this Certification is attached as Exhibit 32.1 (the "Quarterly Report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

	2.	The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In witness whereof, the undersigned have set their hands hereto as of the August 14, 2019.


	By:	/s/ Douglas Beplate
		Douglas Beplate
		Principal Executive Officer

EX-32.2 5 ueec_ex322.htm CERTIFICATION ueec_ex322.htm

EXHIBIT 32.2

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), Nate Knight, Principal Financial Officer of United Health Products, Inc. (the "Company") of the Company, hereby certifies that, to the best of his knowledge:

	1.	The Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, to which this Certification is attached as Exhibit 32.2 (the "Quarterly Report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

	2.	The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In witness whereof, the undersigned have set their hands hereto as of the August 14, 2019.


	By:	/s/ Nate Knight
		Nate Knight
		Principal Financial Officer

EX-101.INS 6 ueec-20190630.xml XBRL INSTANCE DOCUMENT 0001096938 2019-01-01 2019-06-30 0001096938 2019-08-13 0001096938 2019-06-30 0001096938 2018-12-31 0001096938 2019-04-01 2019-06-30 0001096938 2018-04-01 2018-06-30 0001096938 2018-01-01 2018-06-30 0001096938 2017-12-31 0001096938 2018-06-30 0001096938 2018-01-01 2018-12-31 0001096938 ueec:OutstandingAccountsReceivableMember ueec:ThreeCustomersListsMember 2019-01-01 2019-06-30 0001096938 ueec:OutstandingAccountsReceivableMember ueec:ThreeCustomersListsMember 2018-01-01 2018-12-31 0001096938 ueec:NertRvenueMember ueec:CustomersListsMember 2018-01-01 2018-06-30 0001096938 ueec:NertRvenueMember ueec:CustomersListsMember 2019-01-01 2019-06-30 0001096938 ueec:NertRvenueMember ueec:TwoCustomersListsMember 2018-01-01 2018-06-30 0001096938 ueec:DouglasBeplateMember 2019-06-30 0001096938 ueec:DouglasBeplateMember 2019-01-01 2019-06-30 0001096938 ueec:DouglasBeplateMember 2018-12-31 0001096938 ueec:TwoDirectorMember 2019-01-01 2019-06-30 0001096938 ueec:MrNateKnightMember 2018-12-31 0001096938 ueec:EmploymentagreementMember ueec:DouglasBeplateMember 2019-01-01 2019-06-30 0001096938 ueec:DouglasBeplateMember 2019-04-15 0001096938 ueec:DouglasBeplateMember 2019-04-01 2019-04-22 0001096938 ueec:DouglasBeplateMember 2019-04-22 0001096938 ueec:OfficeAdministratorMember 2018-12-31 0001096938 ueec:IssuancesOfSecuritiesMember 2019-01-01 2019-06-30 0001096938 ueec:IssuancesOfSecuritiesMember 2018-01-01 2018-06-30 0001096938 ueec:IssuancesOfSecuritiesMember 2018-12-31 0001096938 ueec:IssuancesOfSecuritiesMember 2019-06-30 0001096938 ueec:EscrowMember 2019-06-30 0001096938 ueec:EscrowMember 2019-01-01 2019-06-30 0001096938 ueec:EscrowMember 2018-01-01 2018-06-30 0001096938 ueec:EscrowMember 2018-01-01 2018-01-31 0001096938 us-gaap:PrivatePlacementMember ueec:NonAffiliatedInvestorsMember 2019-01-01 2019-06-30 0001096938 ueec:TwoDirectorsMember 2019-01-01 2019-06-30 0001096938 ueec:CEOMember 2019-01-01 2019-06-30 0001096938 ueec:CEOMember 2019-06-30 0001096938 ueec:TwoDirectorsMember 2019-06-30 0001096938 ueec:ShareIssuance2019Member srt:ChiefFinancialOfficerMember 2019-01-01 2019-06-30 0001096938 ueec:RestrictedStockUnitsMember 2019-01-01 2019-06-30 0001096938 ueec:EscrowMember srt:ChiefFinancialOfficerMember 2019-06-30 0001096938 ueec:OfficeAdministratorMember 2018-06-30 0001096938 ueec:EscrowMember ueec:OfficeAdministratorMember 2019-06-30 0001096938 ueec:EscrowMember srt:ChiefExecutiveOfficerMember 2019-06-30 0001096938 ueec:IndividualsMember ueec:UnaffiliatedMember 2019-01-01 2019-06-30 0001096938 ueec:IndividualsMember ueec:UnaffiliatedMember 2019-06-30 0001096938 2017-01-01 2017-12-31 0001096938 ueec:FsrIncMember 2019-01-01 2019-06-30 0001096938 ueec:MaximGroupLLCMember ueec:JulyTwoThousandFifteenMember 2019-01-01 2019-06-30 0001096938 ueec:CeoAndCmaMember 2019-01-01 2019-06-30 0001096938 us-gaap:CommonStockMember 2017-12-31 0001096938 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001096938 us-gaap:CommonStockMember 2018-03-31 0001096938 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001096938 us-gaap:CommonStockMember 2018-06-30 0001096938 us-gaap:CommonStockMember 2018-12-31 0001096938 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001096938 us-gaap:CommonStockMember 2019-03-31 0001096938 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001096938 us-gaap:CommonStockMember 2019-06-30 0001096938 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001096938 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001096938 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001096938 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001096938 ueec:AccumulatedDeficitMember 2017-12-31 0001096938 ueec:AccumulatedDeficitMember 2018-01-01 2018-03-31 0001096938 ueec:AccumulatedDeficitMember 2018-03-31 0001096938 ueec:AccumulatedDeficitMember 2018-04-01 2018-06-30 0001096938 ueec:AccumulatedDeficitMember 2018-06-30 0001096938 ueec:AccumulatedDeficitMember 2018-12-31 0001096938 ueec:AccumulatedDeficitMember 2019-01-01 2019-03-31 0001096938 ueec:AccumulatedDeficitMember 2019-03-31 0001096938 ueec:AccumulatedDeficitMember 2019-04-01 2019-06-30 0001096938 ueec:AccumulatedDeficitMember 2019-06-30 0001096938 2018-01-01 2018-03-31 0001096938 2018-03-31 0001096938 2019-01-01 2019-03-31 0001096938 2019-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure United Health Products, Inc. 0001096938 10-Q false --12-31 true false false Yes 2019-06-30 Non-accelerated Filer Q2 2019 176588907

500895

31273

36019

11010

99807

83694

636721

125977

636721

125977

235214

243713

201843 201843

55121

25000

8121

492178

478677

176589

185943

23403837

19198343

-23435883

-19736986

144543

-352700

636721

125977

.001

300000000

.001

185943138

176588907

171793138

176588907

25009

1851

25009

31778

9887

1791

9887

10667

15122

21111

356369

918491

3314861

1297083

214863

242268

571232

918491

3557129

1297083

-556110

-918431

-3542007

-1275972

-156890

3886

3632500

-156890

3886

-156890

-3628614

-713000

-945545

-3698897

-4904586

-0.00

-0.01

-0.02

-0.03

175270956

169787931

173730328

168984736

2723500

674500

156890

-25009

-5641

-16113

6216

12114

-8499

-42492

35000

-833128

-627389

192000

-78500

-10000

1110750

855201

1302750

766701

469622

139312

189942

329254

182500 97000 14150 205000 12000

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;"><div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">United Health Products, Inc. ("United" or the "Company") is a product development and solutions company focusing its growth initiatives on the expanding wound-care industry and disposable medical supplies markets. The Company produces an innovative gauze product that absorbs exudate (fluids which have been discharged from blood vessels) by forming a gel-like substance upon contact.  Interim financial statements are prepared in accordance with GAAP for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Article 8 of Regulation S-X, as appropriate. In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of financial statements for the interim period, have been included. These interim condensed financial statements should be read in conjunction with the Company's audited financial statements and notes for the period ended December 31, 2018 filed with the Securities and Exchange Commission on Form 10-K filed on April 1, 2019. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, as permitted by the SEC, although we believe the disclosures which are made are adequate to make the information presented not misleading.</div></div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;"><div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company's ability to continue as a going concern. The Company intends on financing its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.  The Chief Executive Officer has agreed to advance funds or make payments of the Company's obligations at his discretion. There is no written agreement to continue this support. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ. Trade Accounts Receivable and Concentration Risk We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers which are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credits issued. There was no provision for doubtful accounts recorded at June 30, 2019 and December 31, 2018. The Company recorded $0 and $0 in bad debt expense for the three and six month periods ended June 30, 2019 and 2018, respectively. For the six months ended June 30, 2019, one customer made up 100% of the Companys net revenue and three customers made up 94% of the Companys outstanding accounts receivable balance. For the six months ended June 30, 2018, two customers accounted for 62% and 24% of the Companys net revenue, respectively.  For the year ended December 31, 2018, three customers made up 98.9% of the Companys outstanding accounts receivable balance.  Inventory Inventory is valued at the lower of cost or market using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of raw materials purchased by the Company and finished goods. <div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"><tr><td valign="bottom"></td><td valign="bottom"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">June 30,2019</td><td valign="bottom"></td><td valign="bottom"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">December 31,2018</td><td valign="bottom"> </td></tr><tr bgcolor="#cceeff"><td valign="top">Raw materials</td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">72,121</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">46,121</td><td valign="bottom" width="1%"> </td></tr><tr bgcolor="#ffffff"><td valign="top">Finished goods</td><td valign="bottom" width="1%"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%">27,686</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%">37,573</td><td valign="bottom" width="1%"></td></tr><tr bgcolor="#cceeff"><td></td><td valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%">99,807</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%">83,694</td><td valign="bottom" width="1%"></td></tr></table></div> During the six months ended June 30, 2019 and 2018, the Company determined $0 and $0, respectively, of inventory should be impaired and written-off to cost of goods sold.  Stock Based Compensation The Company issues restricted stock to consultants and employees for various services. Cost for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock for non-employees is measured at the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached and expense is recognized during the term at which the counterparty's performance is earned or at the date the shares are considered non-forfeitable. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services.  Per Share Information Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the shares of common stock held in escrow. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred a net loss for the three and six months ended June 30, 2019 and 2018 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive. The total potential common shares as of June 30, 2019 and 2018, include 50,100,000 of restricted stock units and 14,150,000 of common stock held in escrow, respectively.  New Accounting Pronouncements, Recently Adopted Accounting Pronouncements Leases  In February 2016, the FASB issued Accounting Standards Update (ASU) No. ASU 2016-02, Leases, which amends existing lease accounting guidance, including the requirement to recognize most lease arrangements on the balance sheet. The adoption of this standard will result in the Company recognizing a right-of-use asset representing its rights to use the underlying asset for the lease term with an offsetting lease liability. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has determined there is no impact to the financial statements as the Company does not have any lease agreements. The Company considers all new pronouncements and management has determined that there have been no other recently adopted or issued accounting standards that had or will have a material impact on its financial statements.</div></div></div></div></div></div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">As of June 30, 2019 and December 31, 2018, notes payable to related parties totaled $0 and $8,121, respectively. These amounts are owed to Doug Beplate, our Chief Executive Officer. During the six months ended June 30, 2019, Mr. Beplate advanced the Company $192,000.  On April 22, 2019, the Company agreed to issue to Mr. Beplate convertible demand loans representing all outstanding cash loans made by Mr. Beplate to the Company. For any outstanding loans made on or before April 15, 2019, the loans are convertible at $0.50 per share and for all loans subsequent to April 15, 2019, the notes are convertible at $0.65 per share, in each case at the sole discretion of Mr. Beplate. The Companys stock price on April 22, 2019 was $0.90 which resulted in a beneficial conversion feature of $156,890 which was recorded to interest expense.  During the six months ended June 30, 2019, Mr. Beplate converted $205,000 of notes payable and accrued liabilities at a conversion price of $0.50 into 410,000 shares of common stock. There is $0 remaining as unamortized debt discount.  During the year ended December 31, 2018, Mr. Beplate gave a personal vehicle to an employee of the Company valued at $30,000 in lieu of the Company paying travel expenses and consulting expenses. During 2018, the Company repaid a net amount of $305,207 of the outstanding notes payable balance from proceeds of private placements. These loans were for operating expenses of the Company, are due on demand and have no interest rate.  Per Mr. Beplates services agreement, he receives monthly compensation of $15,000 per month. During the year ended December 31, 2018, he received his entire salary of $180,000 and $61,500 of previously accrued compensation was paid, leaving a balance of $25,000. During the six months ended June 30, 2019, $35,000 of compensation was accrued and $4,879 was converted into stock as mentioned above, leaving a balance of $55,121.  The Company, by board resolution, approved an executive compensation stock bonus package for Mr. Beplate such that upon the sale of all or substantially all of the assets of the Company or other change in control or merger transaction in which the Company is involved, or in the event that no such transaction occurs by December 31, 2019, Mr. Beplate shall receive an amount equal to 15% post issuance of the then outstanding shares of the Company's common stock on a fully diluted basis. It was intended that the board approved stock bonus package will be in lieu of the 5% stock bonus that Mr. Beplate is already entitled to in the event of a sale of the Companys assets or change in control or merger transaction per his services agreement. See Note 4 regarding the granting of Restricted Stock Unit Agreements (RSUs) to various officers, directors and consultants covering an aggregate of 50,100,000 shares of common stock to be issued upon the satisfaction of certain conditions described in Note 4. Included in the RSUs are 33,000,000 to Douglas Beplate in lieu of the compensation stock bonus package described above. During the six months ended June 30, 2019, the Company issued 100,000 shares of common stock to each of two directors for services rendered. The shares had a fair market value of $190,000.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;"><div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">Share issuances 2018 During the six months ended June 30, 2018, the Company issued an aggregate of 19,838,931 shares of common stock. The Company issued 850,000 shares of common stock with a total fair market value of $674,500 for services, 1,276,481 shares of common stock were sold for total proceeds of $850,200, $5,000 of proceeds were received for 7,246 shares of common stock not yet issued and recorded as liability for unissued shares, 62,500 shares of common stock were issued related to $5,000 of previously recorded liability for unissued shares and 14,150,000 shares of common stock with a fair market value of $15,423,500 were issued and placed in escrow. The shares will be released from escrow upon the change of control of the Company. Management is unable to determine when a change of control will occur and $0 has been expensed as of June 30, 2018. The Company also issued 3,500,000 shares of common stock to convert $172,500 of notes payable and $10,000 of accrued interest. The shares were valued at their fair market value of $1.09 which resulted in a loss on debt settlement of $3,632,500.  Share issuances 2019   During the six months ended June 30, 2019, 1,435,769 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $910,750, 400,000 shares of common stock were sold to securities counsel for total cash proceeds of $200,000, 200,000 shares of common stock were issued to securities counsel for services rendered with a fair value of $190,000, 100,000 shares of common stock were issued to each of two directors for services rendered with a fair value of $190,000 and 410,000 shares of common stock were issued to the Companys CEO for conversion of notes payable and accrued liabilities totaling $205,000.   During the six months ended June 30, 2019, the following events occurred with respect to the aforementioned 14,150,000 shares held in escrow:  During the period ended June 30, 2019, the Company issued (i)1,600,000 shares to Nate Knight who is the Chief Financial Officer of the Company, 500,000 shares to the office administrator, who is a person affiliated with the Companys CEO and 50,000 shares to a Technical Product Supervisor, who is the son of the office administrator which had been held in escrow and became vested by the Board of Directors for services provided. These shares had a fair market value of $1.09 per share at the date of issuance and $2,343,500 has been expensed during the six month period ended June 30, 2019. The Company canceled 12,000,000 shares of the aforementioned 14,150,000 shares issued (which were not considered outstanding) in the first quarter of 2019 to various officers, directors and consultants. Restricted stock units The Board approved restricted stock unit agreements with its officers, directors and consultants covering an aggregate of 50,100,000 shares of common stock to be issued and delivered to such persons upon the earlier of (i) a change in control of the Company by a cash tender offer, merger, acquisition or otherwise or (ii) the Company achieving gross revenues of $20,000,000 in gross revenues on a go forward basis, or (iii) the commencement of an event by a third party without the Boards approval to effect, or seek to effect, a change in control of the Company or the Companys management. Restricted Stock Units for 12,000,000 shares were issued in replacement of the 12,000,000 shares that were canceled as described above. <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"><tr><td valign="bottom"></td><td valign="bottom"></td><td valign="bottom" colspan="2"></td><td valign="bottom"></td><td valign="bottom"> </td><td valign="bottom" colspan="2">Weighted </td><td valign="bottom"></td></tr><tr><td valign="bottom"></td><td valign="bottom"></td><td valign="bottom" colspan="2"></td><td valign="bottom"></td><td valign="bottom"> </td><td valign="bottom" colspan="2">Average</td><td valign="bottom"></td></tr><tr><td valign="bottom"></td><td valign="bottom"></td><td valign="bottom" colspan="2"></td><td valign="bottom"></td><td valign="bottom"> </td><td valign="bottom" colspan="2">Grant </td><td valign="bottom"></td></tr><tr><td valign="bottom"></td><td valign="bottom"> </td><td valign="bottom" colspan="2">Number of </td><td valign="bottom"></td><td valign="bottom"> </td><td valign="bottom" colspan="2">Date Fair </td><td valign="bottom"></td></tr><tr><td valign="bottom"></td><td valign="bottom"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">Units </td><td valign="bottom"></td><td valign="bottom"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">Value </td><td valign="bottom"> </td></tr><tr bgcolor="#cceeff"><td valign="top">Total awards outstanding at December 31, 2018 </td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="9%">-</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">-</td><td valign="bottom" width="1%"> </td></tr><tr bgcolor="#ffffff"><td valign="top">Units granted </td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="9%">50,100,000</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">0.94</td><td valign="bottom" width="1%"> </td></tr><tr bgcolor="#cceeff"><td valign="top">Units Exercised/Released </td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="9%">-</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">-</td><td valign="bottom" width="1%"> </td></tr><tr bgcolor="#ffffff"><td valign="top">Units Cancelled/Forfeited </td><td valign="bottom" width="1%"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%">-</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">-</td><td valign="bottom" width="1%"> </td></tr><tr bgcolor="#cceeff"><td valign="top">Total awards outstanding at June 30, 2019</td><td valign="bottom" width="1%"></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%">50,100,000</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">0.94</td><td valign="bottom" width="1%"></td></tr></table> Management is unable to determine when a change of control will occur and as of June 30, 2019, there was $47,094,000 of unrecognized compensation cost related to unvested restricted stock unit awards.</div></div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">There are no legal proceedings pending or threatened against us, except as follows:  During 2017, a Complaint was filed with the United States District Court, Southern District of New York by Steven Safran as Plaintiff against the Company and Douglas Beplate, its CEO, as Defendant. This court case was transferred to the United States District Court in Las Vegas, Nevada. Mr. Safran is seeking damages and monies allegedly owed pursuant to an employment agreement and allegedly unpaid loans of $245,824 provided to Defendants. The Company has denied Plaintiffs allegations and intends to vigorously defend said lawsuit. The parties have held various depositions and the Company has a motion to dismiss which is pending with the court. No accrual has been recorded related to this litigation. In July 2015, the Company entered into a consulting agreement retaining the services of Maxim Group LLC. An amended agreement was executed in January 2018. A total of 4 million shares of common stock were issued to Maxim in exchange for its obligation to perform certain advisory and other services. In the fourth quarter of 2018, the Company notified Maxim of its intent to file for arbitration pursuant to the consulting agreement. Maxim, without providing a similar notice to the Company, immediately filed a complaint with FINRA seeking release of a restrictive legend from a Company stock certificate in the amount of 500,000 shares. The Company filed an affirmative defense that the required notice of arbitration was not provided to the Company prior to filing. The Company also filed a counterclaim for breach of contract seeking restitution of the original 4 million shares issued to Maxim and the Company filed several counterclaims alleging material misrepresentations by Maxim to various entities. The Company intends to vigorously defend Maxims complaint and to pursue to its counterclaims. Currently, the Company and Maxim have a scheduled arbitration with FINRA which will be held in September 2019. Philip Forman, who served in positions as Chairman, a director, Chief Executive Officer and Chief Medical Advisor at various time between 2011 and October 2015, has filed a lawsuit against the Company and our Chief Executive Officer, Douglas Beplate, in the United States District Court of the District of Nevada. The claimant is claiming, among other things, that: the June 25, 2015 Amendment to his November 10, 2014 Employment Agreement with the Company, which terminated the Employment Agreement on October 1, 2015, is not valid because of lack of consideration; that a July 22, 2015 Stock Purchase Agreement pursuant to which the claimant sold Company shares issued to him under the Amendment to a third a party is unenforceable (despite the fact that all payment for the shares under the Stock Purchase Agreement was made); that the plaintiffs 2014 Employment Agreement is enforceable and that he is entitled to cash and stock compensation under that Employment Agreement (without giving regard to the Amendment); that if the Amendment is enforceable, he is entitled to the shares issued under the Amendment (without mention that those shares were sold to a third party under the Stock Purchase Agreement described above); and that the Company and Mr. Beplate defrauded the plaintiff relating to the foregoing. The plaintiff is seeking declaratory judgment regarding the parties relative rights under the Employment Agreement, the Amendment and the Stock Purchase Agreement; money damages of no less than $2,795,000; and punitive damages of $8,280,000. The Company believes that it has meritorious defenses to the matters claimed as well as counterclaims against the claimant. We plan to vigorously respond to the claims and pursue our remedies. We cannot predict the outcome with certainty.  In the Southern District of New York, FSR Inc. commenced a lawsuit in 2018 against Korsair Holdings A.G. seeking among other claims for relief, rescission of the transfer of 3,050,000 shares of United Health Products that FSR sold to Korsair in 2011. Third-Party Plaintiff, JEC Consulting Associates, LLC as Liquidator of LeadDog Capital L.P., Intervenor (Intervenor) in the above matter, filed a third-party complaint against United Health Products, and Douglas K. Beplate (Beplate) alleging among other things that the Company and Mr. Beplate refused to have the Rule 144 restrictive legend removed from the Korsair certificate held by JEC, and concomitantly fraudulently deprive JEC as Liquidator of LeadDog of the ability to sell the Shares in the open market, knowingly, intentionally and directly causing economic harm to LeadDog Capital L.P. Intervenor as Third Party Plaintiff further alleges that the Company and Mr. Beplate as Third-Party Defendants are not only monetarily liable to Third-Party Plaintiff for compensatory damages of $2,500,000 but should be made to pay exemplary damages in an amount determined by the Court, but not less than an equal amount - $2,500,000. Third-Party Plaintiff demands judgment for the above referenced amounts and for the Court to also declare that the 3,050,000 shares are free trading; that Third-Party Plaintiffs rights to 2.5 million of the Shares are superior to the claims of Plaintiff FSR; that Plaintiff FSR has no claim to 2.5 million of the 3,050,000 Shares reflected by the Korsair certificate; that the Company and Mr. Beplate are to instruct its current transfer agent to remove the restrictive legend on the Korsair certificate for the Shares; and an order directing the Company and Mr. Beplate to instruct the Companys transfer agent to exchange the Korsair certificate for new free-trading, unrestricted certificates. The Company believes that it had legal right to decline to instruct the transfer agent to remove the restrictive legend from the Korsair Shares where the ownership of the aforementioned shares have been in dispute and the Korsair shares have not been submitted for transfer to its transfer agent in proper form under the uniform commercial code.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">The Company has evaluated events subsequent to June 30, 2019, through the date whereupon the financial statements were issued and has determined that there are no material events that need to be disclosed.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company's ability to continue as a going concern. The Company intends on financing its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.  The Chief Executive Officer has agreed to advance funds or make payments of the Company's obligations at his discretion. There is no written agreement to continue this support.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">The preparation of financial statements in conformity with generally accepted accounting principles requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;"><div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers which are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credits issued. There was no provision for doubtful accounts recorded at June 30, 2019 and December 31, 2018. The Company recorded $0 and $0 in bad debt expense for the three and six month periods ended June 30, 2019 and 2018, respectively. For the six months ended June 30, 2019, one customer made up 100% of the Companys net revenue and three customers made up 94% of the Companys outstanding accounts receivable balance. For the six months ended June 30, 2018, two customers accounted for 62% and 24% of the Companys net revenue, respectively.  For the year ended December 31, 2018, three customers made up 98.9% of the Companys outstanding accounts receivable balance. </div></div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;"><div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">Inventory is valued at the lower of cost or market using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of raw materials purchased by the Company and finished goods. <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"><tr><td valign="bottom"></td><td valign="bottom"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">June 30,2019</td><td valign="bottom"></td><td valign="bottom"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">December 31,2018</td><td valign="bottom"> </td></tr><tr bgcolor="#cceeff"><td valign="top">Raw materials</td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">72,121</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">46,121</td><td valign="bottom" width="1%"> </td></tr><tr bgcolor="#ffffff"><td valign="top">Finished goods</td><td valign="bottom" width="1%"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%">27,686</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%">37,573</td><td valign="bottom" width="1%"></td></tr><tr bgcolor="#cceeff"><td></td><td valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%">99,807</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%">83,694</td><td valign="bottom" width="1%"></td></tr></table> During the six months ended June 30, 2019 and 2018, the Company determined $0 and $0, respectively, of inventory should be impaired and written-off to cost of goods sold. </div></div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;">The Company issues restricted stock to consultants and employees for various services. Cost for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock for non-employees is measured at the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached and expense is recognized during the term at which the counterparty's performance is earned or at the date the shares are considered non-forfeitable. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;"><div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the shares of common stock held in escrow. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred a net loss for the three and six months ended June 30, 2019 and 2018 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive. The total potential common shares as of June 30, 2019 and 2018, include 50,100,000 of restricted stock units and 14,150,000 of common stock held in escrow, respectively.</div></div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"><tr><td valign="bottom"></td><td valign="bottom"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">June 30,2019</td><td valign="bottom"></td><td valign="bottom"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">December 31,2018</td><td valign="bottom"> </td></tr><tr bgcolor="#cceeff"><td valign="top">Raw materials</td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">72,121</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">46,121</td><td valign="bottom" width="1%"> </td></tr><tr bgcolor="#ffffff"><td valign="top">Finished goods</td><td valign="bottom" width="1%"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%">27,686</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%">37,573</td><td valign="bottom" width="1%"></td></tr><tr bgcolor="#cceeff"><td></td><td valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%">99,807</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%">83,694</td><td valign="bottom" width="1%"></td></tr></table> </div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;"><div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"><tr><td valign="bottom"></td><td valign="bottom"></td><td valign="bottom" colspan="2"></td><td valign="bottom"></td><td valign="bottom"> </td><td valign="bottom" colspan="2">Weighted </td><td valign="bottom"></td></tr><tr><td valign="bottom"></td><td valign="bottom"></td><td valign="bottom" colspan="2"></td><td valign="bottom"></td><td valign="bottom"> </td><td valign="bottom" colspan="2">Average</td><td valign="bottom"></td></tr><tr><td valign="bottom"></td><td valign="bottom"></td><td valign="bottom" colspan="2"></td><td valign="bottom"></td><td valign="bottom"> </td><td valign="bottom" colspan="2">Grant </td><td valign="bottom"></td></tr><tr><td valign="bottom"></td><td valign="bottom"> </td><td valign="bottom" colspan="2">Number of </td><td valign="bottom"></td><td valign="bottom"> </td><td valign="bottom" colspan="2">Date Fair </td><td valign="bottom"></td></tr><tr><td valign="bottom"></td><td valign="bottom"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">Units </td><td valign="bottom"></td><td valign="bottom"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">Value </td><td valign="bottom"> </td></tr><tr bgcolor="#cceeff"><td valign="top">Total awards outstanding at December 31, 2018 </td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="9%">-</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">-</td><td valign="bottom" width="1%"> </td></tr><tr bgcolor="#ffffff"><td valign="top">Units granted </td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="9%">50,100,000</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">0.94</td><td valign="bottom" width="1%"> </td></tr><tr bgcolor="#cceeff"><td valign="top">Units Exercised/Released </td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="9%">-</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">-</td><td valign="bottom" width="1%"> </td></tr><tr bgcolor="#ffffff"><td valign="top">Units Cancelled/Forfeited </td><td valign="bottom" width="1%"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%">-</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">-</td><td valign="bottom" width="1%"> </td></tr><tr bgcolor="#cceeff"><td valign="top">Total awards outstanding at June 30, 2019</td><td valign="bottom" width="1%"></td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%"> </td><td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%">50,100,000</td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"> </td><td valign="bottom" width="1%">$</td><td valign="bottom" width="9%">0.94</td><td valign="bottom" width="1%"></td></tr></table> </div></div>

72121

46121

27686

37573

99807

83694

14150000

50100000 50100000

14150000

0.94

0.989

0.62

0.24

33000000

305207

86500

55121

8121

35000

61500 61500 190000

100000

180000 Mr. Beplate shall receive an amount equal to 15% post issuance of the then outstanding shares of the Company's common stock on a fully diluted basis. It was intended that the board approved stock bonus package will be in lieu of the 5% stock bonus that Mr. Beplate is already entitled to in the event of a sale of the Companys assets or change in control or merger transaction per his services agreement. See Note 4 regarding the granting of Restricted Stock Unit Agreements (RSUs) to various officers, directors and consultants covering an aggregate of 50,100,000 shares of common stock to be issued upon the satisfaction of certain conditions described in Note 4. Included in the RSUs are 33,000,000 to Douglas Beplate in lieu of the compensation stock bonus package described above.

180000

1.09

15000

192000

0.50

50100000

4879

410000

30000

205000

156890

0.90

0.65

0.50

1.09

850200

190000

1276481

5000

19838931

7246

15423500 850000 5000 62500 47094000 2343500

-3632500

3500000

172500

10000

674500

15423500

14150000 14150000 14150000

1435769

200000

910750 200000 190000

400000

190000

100000

410000

205000

20000000

50100000

12000000 12000000 12000000

1600000

1.09

500000

50000

1.09

Complaint was filed with the United States District Court, Southern District of New York by Steven Safran as Plaintiff against the Company and Douglas Beplate, its CEO, as Defendant. This court case was transferred to the United States District Court in Las Vegas, Nevada. Mr. Safran is seeking damages and monies allegedly owed pursuant to an employment agreement and allegedly unpaid loans of $245,824 provided to Defendants. The Company has denied Plaintiff's allegations and intends to vigorously defend said lawsuit. 800000

In the Southern District of New York, FSR Inc commenced a lawsuit in 2018 against Korsair Holdings A.G. seeking among other claims for relief, rescission of the transfer of 3,050,000 shares of United Health Products that FSR sold to Korsair in 2011. Third-Party Plaintiff, JEC Consulting Associates, LLC as Liquidator of LeadDog Capital L.P., Intervenor (“Intervenor”) in the above matter, filed a third-party complaint against United Health Products, and Douglas K. Beplate (“Beplate”) alleging among other things that the Company and Mr. Beplate refused to have the Rule 144 restrictive legend removed from the Korsair certificate held by JEC, and concomitantly fraudulently deprive JEC as Liquidator of LeadDog of the ability to sell the Shares in the open market, knowingly, intentionally and directly causing economic harm to LeadDog Capital L.P. Intervenor as Third Party Plaintiff further alleges that the Company and Mr. Beplate as Third-Party Defendants are not only monetarily liable to Third-Party Plaintiff for compensatory damages of $2,500,000 but should be made to pay exemplary damages in an amount determined by the Court, but not less than an equal amount - $2,500,000. Third-Party Plaintiff demands judgment for the above referenced amounts and for the Court to also declare that the 3,050,000 shares are free trading; that Third-Party Plaintiff’s rights to 2.5 million of the Shares are superior to the claims of Plaintiff FSR; that Plaintiff FSR has no claim to 2.5 million of the 3,050,000 Shares reflected by the Korsair certificate

4000000

500000

2795000

8280000

201843

211843

-10000

201843

2414059

50100000

0.94

164969663

3500000 50000 440725 62500 14150000

183172888

800000 698697 137059

184808644

185943138

400000 150000 -12000000

174493138

1685769 410000

176588907

164969

3500 50 441 63 14150

183173

800 699 137

184809

185943

400 150 -12000

174493

1686 410

176589

13304617

3811500 54450 275660 4937 -14150

17437014

619200 481401 91863

18629478

19198343

2343500 379600 74850 12000

22008293

1034064 204590 156890

23403837

-13730851

-3990041

-17720892

-914545

-18635437

-19736986

-2985897

-22721883

-713000

-23435883

-261265

3815000 54500 276101 5000

-3990041

-100705

620000 482100 92000

-914545

178850

2343500 380000 75000

-2985897

-540097

1035750 205000 156890

-713000

<div style="font: 10pt TIMES NEW ROMAN; text-align: justify;"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"><tr><td valign="bottom"> </td><td valign="bottom"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="10%" colspan="2">2019</td><td valign="bottom"></td><td valign="bottom"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="10%" colspan="2">2018</td><td valign="bottom"></td></tr><tr bgcolor="#cceeff"><td valign="top">Balance, beginning</td><td valign="bottom"></td><td valign="bottom" width="1%">$</td><td valign="bottom" width="8%">201,843</td><td valign="bottom"></td><td valign="bottom"></td><td valign="bottom" width="1%">$</td><td valign="bottom" width="8%">211,843</td><td valign="bottom" width="1%"></td></tr><tr bgcolor="#ffffff"><td valign="top">Issuance of shares in satisfaction of liability</td><td valign="bottom"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="8%">-</td><td valign="bottom"></td><td valign="bottom"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="8%">(10,000</td><td valign="bottom" width="1%">)</td></tr><tr bgcolor="#cceeff"><td valign="top">Balance, ending</td><td valign="bottom"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">$</td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="8%">201,843</td><td valign="bottom"></td><td valign="bottom"></td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">$</td><td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="8%">201,843</td><td valign="bottom" width="1%"></td></tr></table> </div>

EX-101.SCH 7 ueec-20190630.xsd XBRL TAXONOMY EXTENSION SCHEMA 0000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Statement of Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Organization and Basis of Preparation link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - Issuances of Securities link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - Liability for Unissued Shares link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - Issuances of Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - Liability for Unissued Shares (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - Issuances of Securities (Details) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - Issuances of Securities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - Litigation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - Liability for Unissued Shares (Details) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - Liability for Unissued Shares (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 8 ueec-20190630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Condensed Balance Sheets Current Assets Cash and Cash Equivalents Accounts Receivable Inventory Total current assets TOTAL ASSETS Current Liabilities Accounts payable and accrued expenses Liability for unissued shares Accrued liabilities - related parties Notes payable - related parties Total current liabilities Commitments and Contingencies Stockholders' Equity (Deficiency) Common Stock - $.001 par value, 300,000,000 Shares Authorized, 176,588,907 and 185,943,138 shares issued at June 30, 2019 and December 31, 2018, respectively and 176,588,907 and 171,793,138 shares outstanding at June 30, 2019 and December 31, 2018, respectively Additional Paid-In Capital Accumulated Deficit Total Stockholders' Equity (Deficiency) TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY) Stockholders' Equity (Deficiency) Common stock, shares par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Condensed Statements of Operations (Unaudited) Revenues Cost of goods sold Gross profit Operating Costs and Expenses Selling, general and administrative expenses Research and development Total Operating Expenses Loss from Operations Other Income (Expenses) Interest Expense Other Income Loss on debt settlement [Gain (Loss) on Extinguishment of Debt] Total other income (expenses) [Other Nonoperating Income (Expense)] Net Loss Net Loss per common share: Basic and diluted Weighted average number of shares outstanding Condensed Statement of Stockholders' Deficit Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Shares Additional Paid-in Capital Accumulated Deficit [Accumulated Deficit] Beginning Balance, Shares [Shares, Issued] Beginning Balance, Amount Issuance of shares for notes payable and accrued interest, Shares Issuance of common stock for services, Shares Sale of common stock, Shares Shares issued for liability of unissued shares, Shares Shares held in escrow, Shares Net Loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Vesting of shares held in escrow, Shares Cancellation of escrow shares, Shares Issuance of shares for notes payable and accrued liabilities - related party, Shares Beneficial conversion feature Issuance of shares for notes payable and accrued interest, Amount Issuance of common stock for services, Amount Sale of common stock, Amount Shares issued for liability of unissued shares, Amount Shares held in escrow, Amount Vesting of shares held in escrow, Amount Cancellation of escrow shares, Amount Issuance of shares for notes payable and accrued liabilities - related party, Amount Beginning Balance, Shares Beginning Balance, Amount Condensed Statements of Cash Flows (Unaudited) Cash Flows from Operating Activities: Net (Loss) Adjustments to Reconcile net (loss) to Net Cash Used In Operating Activities: Stock based compensation Loss on settlement of debt Amortization of debt discount Changes in assets and liabilities: Accounts Receivable [Increase (Decrease) in Accounts Receivable] Inventory [Increase (Decrease) in Inventories] Prepaid and other current assets Accounts payable and accrued expenses [Increase (Decrease) in Accounts Payable and Accrued Liabilities] Accrued liabilities - related party Net Cash Used In Operating Activities Cash Flows from Investing Activities: Cash Flows from Financing Activities: Proceeds from related party Repayments to related party Repayment on notes payable Proceeds from sale of common stock Cash flow provided by financing activities Increase in Cash and Cash Equivalents Cash and Cash Equivalents - Beginning of period CASH AND CASH EQUIVALENTS - END OF PERIOD Supplemental cash flow information: Cash paid for interest Cash paid for income taxes Non-cash Investing & Financing Activities: Shares issued for debt and accrued interest Shares issued related to liability for unissued shares Shares issued and held in escrow Share issued for notes payable and accrued liabilities - related party Cancellation of shares Organization and Basis of Preparation Note 1. Organization and Basis of Preparation Significant Accounting Policies Note 2. Significant Accounting Policies Related Party Transactions Note 3. Related Party Transactions Issuances of Securities Note 4. Issuances of Securities Litigation Note 5. Litigation Liability for Unissued Shares Note 6. Liability for Unissued Shares Subsequent Events Note 7. Subsequent Events Significant Accounting Policies (Policies) Going Concern Use of Estimates Trade Accounts Receivable and Concentration Risk Inventory Inventory, Policy [Policy Text Block] Stock Based Compensation Per Share Information New Accounting Pronouncements, Recently Adopted Accounting Pronouncements Significant Accounting Policies (Tables) Schedule of inventory Issuances of Securities (Tables) Restricted stock units Schedule of liabilities for unissued shares Significant Accounting Policies (Details) Raw materials Finished goods Total inventory Significant Accounting Policies (Details Narrative) Concentration Risk By Type Axis Finite Lived Intangible Assets By Major Class Axis Outstanding accounts receivable [Member] Three customers [Member] Net revenue [Member] One customer [Member] Two customers [Member] Bad debt expense Write-off of inventory Common stock held in escrow Restricted stock units [Restricted stock units] Concentration risk, percentage Related Party Transactions (Details Narrative) Related Party Transactions By Related Party Axis Title of Individual [Axis] Assets Sold Under Agreements To Repurchase Axis Douglas Beplate [Member] Two Directors [Member] Mr. Nate Knight [Member] Employment agreement [Member] Office Administrator [Member] Accrued liabilities - related party Notes payable - related parties [Notes Payable, Related Parties, Noncurrent] Accrued compensation Payment of compensation Salary Executive compensation stock bonus package, description Salary [Accrued Salaries, Current] Repayment of notes payable Notes payable - related parties [Notes Payable, Related Parties] Officers Compensation Proceeds from related party Convertible loans per share Convertible notes per share Stock price per share Restricted stock units Interest expense Converted notes payable and accrued liabilities Unamortized debt discount EX-101.CAL 9 ueec-20190630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 10 ueec-20190630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 11 ueec-20190630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 13, 2019
Document And Entity Information
Entity Registrant Name	United Health Products, Inc.
Entity Central Index Key	0001096938
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2019
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019
Entity Common Stock Shares Outstanding		176,588,907

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current Assets
Cash and Cash Equivalents	$ 500,895	$ 31,273
Accounts Receivable	36,019	11,010
Inventory	99,807	83,694
Total current assets	636,721	125,977
TOTAL ASSETS	636,721	125,977
Current Liabilities
Accounts payable and accrued expenses	235,214	243,713
Liability for unissued shares	201,843	201,843
Accrued liabilities - related parties	55,121	25,000
Notes payable - related parties		8,121
Total current liabilities	492,178	478,677
Commitments and Contingencies
Stockholders' Equity (Deficiency)
Common Stock - $.001 par value, 300,000,000 Shares Authorized, 176,588,907 and 185,943,138 shares issued at June 30, 2019 and December 31, 2018, respectively and 176,588,907 and 171,793,138 shares outstanding at June 30, 2019 and December 31, 2018, respectively	176,589	185,943
Additional Paid-In Capital	23,403,837	19,198,343
Accumulated Deficit	(23,435,883)	(19,736,986)
Total Stockholders' Equity (Deficiency)	144,543	(352,700)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)	$ 636,721	$ 125,977

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Stockholders' Equity (Deficiency)
Common stock, shares par value	$ .001	$ .001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	176,588,907	185,943,138
Common stock, shares outstanding	176,588,907	171,793,138

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Condensed Statements of Operations (Unaudited)
Revenues	$ 25,009	$ 1,851	$ 25,009	$ 31,778
Cost of goods sold	9,887	1,791	9,887	10,667
Gross profit	15,122	60	15,122	21,111
Operating Costs and Expenses
Selling, general and administrative expenses	356,369	918,491	3,314,861	1,297,083
Research and development	214,863		242,268
Total Operating Expenses	571,232	918,491	3,557,129	1,297,083
Loss from Operations	(556,110)	(918,431)	(3,542,007)	(1,275,972)
Other Income (Expenses)
Interest Expense	(156,890)		(156,890)
Other Income		3,886		3,886
Loss on debt settlement				(3,632,500)
Total other income (expenses)	(156,890)	3,886	(156,890)	(3,628,614)
Net Loss	$ (713,000)	$ (945,545)	$ (3,698,897)	$ (4,904,586)
Net Loss per common share:
Basic and diluted	$ (0.00)	$ (0.01)	$ (0.02)	$ (0.03)
Weighted average number of shares outstanding	175,270,956	169,787,931	173,730,328	168,984,736

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Statement of Stockholders' Deficit - USD ($)	Total	Common Stock Shares	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance, Shares at Dec. 31, 2017		164,969,663
Beginning Balance, Amount at Dec. 31, 2017	$ (261,265)	$ 164,969	$ 13,304,617	$ (13,730,851)
Issuance of shares for notes payable and accrued interest, Shares		3,500,000
Issuance of common stock for services, Shares		50,000
Sale of common stock, Shares		440,725
Shares issued for liability of unissued shares, Shares		62,500
Shares held in escrow, Shares		14,150,000
Net Loss	(3,990,041)			(3,990,041)
Issuance of shares for notes payable and accrued interest, Amount	3,815,000	3,500	3,811,500
Issuance of common stock for services, Amount	54,500	50	54,450
Sale of common stock, Amount	276,101	441	275,660
Shares issued for liability of unissued shares, Amount	5,000	63	4,937
Shares held in escrow, Amount		$ 14,150	(14,150)
Beginning Balance, Shares at Mar. 31, 2018		183,172,888
Beginning Balance, Amount at Mar. 31, 2018	(100,705)	$ 183,173	17,437,014	(17,720,892)
Issuance of common stock for services, Shares		800,000
Sale of common stock, Shares		698,697
Shares issued for liability of unissued shares, Shares		137,059
Net Loss	(914,545)			(914,545)
Issuance of common stock for services, Amount	620,000	800	619,200
Sale of common stock, Amount	482,100	699	481,401
Shares issued for liability of unissued shares, Amount	92,000	$ 137	91,863
Beginning Balance, Shares at Jun. 30, 2018		184,808,644
Beginning Balance, Amount at Jun. 30, 2018	178,850	$ 184,809	18,629,478	(18,635,437)
Beginning Balance, Shares at Dec. 31, 2018		185,943,138
Beginning Balance, Amount at Dec. 31, 2018	(352,700)	$ 185,943	19,198,343	(19,736,986)
Issuance of common stock for services, Shares		400,000
Sale of common stock, Shares		150,000
Net Loss	(2,985,897)			(2,985,897)
Vesting of shares held in escrow, Shares
Cancellation of escrow shares, Shares		(12,000,000)
Issuance of common stock for services, Amount	380,000	$ 400	379,600
Sale of common stock, Amount	75,000	150	74,850
Vesting of shares held in escrow, Amount	2,343,500		2,343,500
Cancellation of escrow shares, Amount		$ (12,000)	12,000
Beginning Balance, Shares at Mar. 31, 2019		174,493,138
Beginning Balance, Amount at Mar. 31, 2019	(540,097)	$ 174,493	22,008,293	(22,721,883)
Sale of common stock, Shares		1,685,769
Net Loss	(713,000)			(713,000)
Issuance of shares for notes payable and accrued liabilities - related party, Shares		410,000
Beneficial conversion feature	156,890		156,890
Sale of common stock, Amount	1,035,750	1,686	1,034,064
Issuance of shares for notes payable and accrued liabilities - related party, Amount	205,000	$ 410	204,590
Beginning Balance, Shares at Jun. 30, 2019		176,588,907
Beginning Balance, Amount at Jun. 30, 2019	$ 144,543	$ 176,589	$ 23,403,837	$ (23,435,883)

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash Flows from Operating Activities:
Net (Loss)	$ (3,698,897)	$ (4,904,586)
Adjustments to Reconcile net (loss) to Net Cash Used In Operating Activities:
Stock based compensation	2,723,500	674,500
Loss on settlement of debt		3,632,500
Amortization of debt discount	156,890
Changes in assets and liabilities:
Accounts Receivable	(25,009)	(5,641)
Inventory	(16,113)	6,216
Prepaid and other current assets		12,114
Accounts payable and accrued expenses	(8,499)	(42,492)
Accrued liabilities - related party	35,000
Net Cash Used In Operating Activities	(833,128)	(627,389)
Cash Flows from Investing Activities:
Cash Flows from Financing Activities:
Proceeds from related party	192,000
Repayments to related party		(78,500)
Repayment on notes payable		(10,000)
Proceeds from sale of common stock	1,110,750	855,201
Cash flow provided by financing activities	1,302,750	766,701
Increase in Cash and Cash Equivalents	469,622	139,312
Cash and Cash Equivalents - Beginning of period	31,273	189,942
CASH AND CASH EQUIVALENTS - END OF PERIOD	500,895	329,254
Supplemental cash flow information:
Cash paid for interest
Cash paid for income taxes
Non-cash Investing & Financing Activities:
Shares issued for debt and accrued interest		182,500
Shares issued related to liability for unissued shares		97,000
Shares issued and held in escrow		14,150
Share issued for notes payable and accrued liabilities - related party	$ 205,000
Cancellation of shares	$ 12,000

XML 18 R7.htm IDEA: XBRL DOCUMENT

Organization and Basis of Preparation	6 Months Ended
Organization and Basis of Preparation	Jun. 30, 2019
Organization and Basis of Preparation
Note 1. Organization and Basis of Preparation	United Health Products, Inc. ("United" or the "Company") is a product development and solutions company focusing its growth initiatives on the expanding wound-care industry and disposable medical supplies markets. The Company produces an innovative gauze product that absorbs exudate (fluids which have been discharged from blood vessels) by forming a gel-like substance upon contact. Interim financial statements are prepared in accordance with GAAP for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Article 8 of Regulation S-X, as appropriate. In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of financial statements for the interim period, have been included. These interim condensed financial statements should be read in conjunction with the Company's audited financial statements and notes for the period ended December 31, 2018 filed with the Securities and Exchange Commission on Form 10-K filed on April 1, 2019. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, as permitted by the SEC, although we believe the disclosures which are made are adequate to make the information presented not misleading.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

6 Months Ended

Jun. 30, 2019

Significant Accounting Policies

Note 2. Significant Accounting Policies

Going Concern

The Chief Executive Officer has agreed to advance funds or make payments of the Company's obligations at his discretion. There is no written agreement to continue this support.

Use of Estimates

Trade Accounts Receivable and Concentration Risk

For the six months ended June 30, 2019, one customer made up 100% of the Companys net revenue and three customers made up 94% of the Companys outstanding accounts receivable balance.

For the six months ended June 30, 2018, two customers accounted for 62% and 24% of the Companys net revenue, respectively.

For the year ended December 31, 2018, three customers made up 98.9% of the Companys outstanding accounts receivable balance.

Inventory

Inventory is valued at the lower of cost or market using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of raw materials purchased by the Company and finished goods.

	June 30, 2019		December 31, 2018
Raw materials	$	72,121	$	46,121
Finished goods		27,686		37,573
	$	99,807	$	83,694

During the six months ended June 30, 2019 and 2018, the Company determined $0 and $0, respectively, of inventory should be impaired and written-off to cost of goods sold.

Stock Based Compensation

Per Share Information

The total potential common shares as of June 30, 2019 and 2018, include 50,100,000 of restricted stock units and 14,150,000 of common stock held in escrow, respectively.

New Accounting Pronouncements, Recently Adopted Accounting Pronouncements

Leases

XML 20 R9.htm IDEA: XBRL DOCUMENT

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2019
Related Party Transactions
Note 3. Related Party Transactions	As of June 30, 2019 and December 31, 2018, notes payable to related parties totaled $0 and $8,121, respectively. These amounts are owed to Doug Beplate, our Chief Executive Officer. During the six months ended June 30, 2019, Mr. Beplate advanced the Company $192,000. On April 22, 2019, the Company agreed to issue to Mr. Beplate convertible demand loans representing all outstanding cash loans made by Mr. Beplate to the Company. For any outstanding loans made on or before April 15, 2019, the loans are convertible at $0.50 per share and for all loans subsequent to April 15, 2019, the notes are convertible at $0.65 per share, in each case at the sole discretion of Mr. Beplate. The Companys stock price on April 22, 2019 was $0.90 which resulted in a beneficial conversion feature of $156,890 which was recorded to interest expense. During the six months ended June 30, 2019, Mr. Beplate converted $205,000 of notes payable and accrued liabilities at a conversion price of $0.50 into 410,000 shares of common stock. There is $0 remaining as unamortized debt discount. During the year ended December 31, 2018, Mr. Beplate gave a personal vehicle to an employee of the Company valued at $30,000 in lieu of the Company paying travel expenses and consulting expenses. During 2018, the Company repaid a net amount of $305,207 of the outstanding notes payable balance from proceeds of private placements. These loans were for operating expenses of the Company, are due on demand and have no interest rate. Per Mr. Beplates services agreement, he receives monthly compensation of $15,000 per month. During the year ended December 31, 2018, he received his entire salary of $180,000 and $61,500 of previously accrued compensation was paid, leaving a balance of $25,000. During the six months ended June 30, 2019, $35,000 of compensation was accrued and $4,879 was converted into stock as mentioned above, leaving a balance of $55,121. The Company, by board resolution, approved an executive compensation stock bonus package for Mr. Beplate such that upon the sale of all or substantially all of the assets of the Company or other change in control or merger transaction in which the Company is involved, or in the event that no such transaction occurs by December 31, 2019, Mr. Beplate shall receive an amount equal to 15% post issuance of the then outstanding shares of the Company's common stock on a fully diluted basis. It was intended that the board approved stock bonus package will be in lieu of the 5% stock bonus that Mr. Beplate is already entitled to in the event of a sale of the Companys assets or change in control or merger transaction per his services agreement. See Note 4 regarding the granting of Restricted Stock Unit Agreements (RSUs) to various officers, directors and consultants covering an aggregate of 50,100,000 shares of common stock to be issued upon the satisfaction of certain conditions described in Note 4. Included in the RSUs are 33,000,000 to Douglas Beplate in lieu of the compensation stock bonus package described above. During the six months ended June 30, 2019, the Company issued 100,000 shares of common stock to each of two directors for services rendered. The shares had a fair market value of $190,000.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Issuances of Securities

6 Months Ended

Jun. 30, 2019

Issuances of Securities

Note 4. Issuances of Securities

Share issuances 2018

Share issuances 2019

During the six months ended June 30, 2019, 1,435,769 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $910,750, 400,000 shares of common stock were sold to securities counsel for total cash proceeds of $200,000, 200,000 shares of common stock were issued to securities counsel for services rendered with a fair value of $190,000, 100,000 shares of common stock were issued to each of two directors for services rendered with a fair value of $190,000 and 410,000 shares of common stock were issued to the Companys CEO for conversion of notes payable and accrued liabilities totaling $205,000. During the six months ended June 30, 2019, the following events occurred with respect to the aforementioned 14,150,000 shares held in escrow:

During the period ended June 30, 2019, the Company issued (i)1,600,000 shares to Nate Knight who is the Chief Financial Officer of the Company, 500,000 shares to the office administrator, who is a person affiliated with the Companys CEO and 50,000 shares to a Technical Product Supervisor, who is the son of the office administrator which had been held in escrow and became vested by the Board of Directors for services provided. These shares had a fair market value of $1.09 per share at the date of issuance and $2,343,500 has been expensed during the six month period ended June 30, 2019.

Restricted stock units

The Board approved restricted stock unit agreements with its officers, directors and consultants covering an aggregate of 50,100,000 shares of common stock to be issued and delivered to such persons upon the earlier of (i) a change in control of the Company by a cash tender offer, merger, acquisition or otherwise or (ii) the Company achieving gross revenues of $20,000,000 in gross revenues on a go forward basis, or (iii) the commencement of an event by a third party without the Boards approval to effect, or seek to effect, a change in control of the Company or the Companys management. Restricted Stock Units for 12,000,000 shares were issued in replacement of the 12,000,000 shares that were canceled as described above.

			Weighted
			Average
			Grant
	Number of		Date Fair
	Units		Value
Total awards outstanding at December 31, 2018		-	$	-
Units granted		50,100,000	$	0.94
Units Exercised/Released		-	$	-
Units Cancelled/Forfeited		-	$	-
Total awards outstanding at June 30, 2019		50,100,000	$	0.94

XML 22 R11.htm IDEA: XBRL DOCUMENT

Litigation	6 Months Ended
Litigation	Jun. 30, 2019
Litigation
Note 5. Litigation	There are no legal proceedings pending or threatened against us, except as follows: During 2017, a Complaint was filed with the United States District Court, Southern District of New York by Steven Safran as Plaintiff against the Company and Douglas Beplate, its CEO, as Defendant. This court case was transferred to the United States District Court in Las Vegas, Nevada. Mr. Safran is seeking damages and monies allegedly owed pursuant to an employment agreement and allegedly unpaid loans of $245,824 provided to Defendants. The Company has denied Plaintiffs allegations and intends to vigorously defend said lawsuit. The parties have held various depositions and the Company has a motion to dismiss which is pending with the court. No accrual has been recorded related to this litigation. In July 2015, the Company entered into a consulting agreement retaining the services of Maxim Group LLC. An amended agreement was executed in January 2018. A total of 4 million shares of common stock were issued to Maxim in exchange for its obligation to perform certain advisory and other services. In the fourth quarter of 2018, the Company notified Maxim of its intent to file for arbitration pursuant to the consulting agreement. Maxim, without providing a similar notice to the Company, immediately filed a complaint with FINRA seeking release of a restrictive legend from a Company stock certificate in the amount of 500,000 shares. The Company filed an affirmative defense that the required notice of arbitration was not provided to the Company prior to filing. The Company also filed a counterclaim for breach of contract seeking restitution of the original 4 million shares issued to Maxim and the Company filed several counterclaims alleging material misrepresentations by Maxim to various entities. The Company intends to vigorously defend Maxims complaint and to pursue to its counterclaims. Currently, the Company and Maxim have a scheduled arbitration with FINRA which will be held in September 2019. Philip Forman, who served in positions as Chairman, a director, Chief Executive Officer and Chief Medical Advisor at various time between 2011 and October 2015, has filed a lawsuit against the Company and our Chief Executive Officer, Douglas Beplate, in the United States District Court of the District of Nevada. The claimant is claiming, among other things, that: the June 25, 2015 Amendment to his November 10, 2014 Employment Agreement with the Company, which terminated the Employment Agreement on October 1, 2015, is not valid because of lack of consideration; that a July 22, 2015 Stock Purchase Agreement pursuant to which the claimant sold Company shares issued to him under the Amendment to a third a party is unenforceable (despite the fact that all payment for the shares under the Stock Purchase Agreement was made); that the plaintiffs 2014 Employment Agreement is enforceable and that he is entitled to cash and stock compensation under that Employment Agreement (without giving regard to the Amendment); that if the Amendment is enforceable, he is entitled to the shares issued under the Amendment (without mention that those shares were sold to a third party under the Stock Purchase Agreement described above); and that the Company and Mr. Beplate defrauded the plaintiff relating to the foregoing. The plaintiff is seeking declaratory judgment regarding the parties relative rights under the Employment Agreement, the Amendment and the Stock Purchase Agreement; money damages of no less than $2,795,000; and punitive damages of $8,280,000. The Company believes that it has meritorious defenses to the matters claimed as well as counterclaims against the claimant. We plan to vigorously respond to the claims and pursue our remedies. We cannot predict the outcome with certainty. In the Southern District of New York, FSR Inc. commenced a lawsuit in 2018 against Korsair Holdings A.G. seeking among other claims for relief, rescission of the transfer of 3,050,000 shares of United Health Products that FSR sold to Korsair in 2011. Third-Party Plaintiff, JEC Consulting Associates, LLC as Liquidator of LeadDog Capital L.P., Intervenor (Intervenor) in the above matter, filed a third-party complaint against United Health Products, and Douglas K. Beplate (Beplate) alleging among other things that the Company and Mr. Beplate refused to have the Rule 144 restrictive legend removed from the Korsair certificate held by JEC, and concomitantly fraudulently deprive JEC as Liquidator of LeadDog of the ability to sell the Shares in the open market, knowingly, intentionally and directly causing economic harm to LeadDog Capital L.P. Intervenor as Third Party Plaintiff further alleges that the Company and Mr. Beplate as Third-Party Defendants are not only monetarily liable to Third-Party Plaintiff for compensatory damages of $2,500,000 but should be made to pay exemplary damages in an amount determined by the Court, but not less than an equal amount - $2,500,000. Third-Party Plaintiff demands judgment for the above referenced amounts and for the Court to also declare that the 3,050,000 shares are free trading; that Third-Party Plaintiffs rights to 2.5 million of the Shares are superior to the claims of Plaintiff FSR; that Plaintiff FSR has no claim to 2.5 million of the 3,050,000 Shares reflected by the Korsair certificate; that the Company and Mr. Beplate are to instruct its current transfer agent to remove the restrictive legend on the Korsair certificate for the Shares; and an order directing the Company and Mr. Beplate to instruct the Companys transfer agent to exchange the Korsair certificate for new free-trading, unrestricted certificates. The Company believes that it had legal right to decline to instruct the transfer agent to remove the restrictive legend from the Korsair Shares where the ownership of the aforementioned shares have been in dispute and the Korsair shares have not been submitted for transfer to its transfer agent in proper form under the uniform commercial code.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Liability for Unissued Shares

6 Months Ended

Jun. 30, 2019

Liability for Unissued Shares

Note 6. Liability for Unissued Shares

	2019		2018
Balance, beginning	$	201,843	$	211,843
Issuance of shares in satisfaction of liability		-		(10,000	)
Balance, ending	$	201,843	$	201,843

The total number of shares granted but unissued were 2,414,059 and 2,414,059, as of June 30, 2019 and December 31, 2018, respectively.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2019
Subsequent Events
Note 7. Subsequent Events	The Company has evaluated events subsequent to June 30, 2019, through the date whereupon the financial statements were issued and has determined that there are no material events that need to be disclosed.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2019

Significant Accounting Policies (Policies)

Going Concern

The Chief Executive Officer has agreed to advance funds or make payments of the Company's obligations at his discretion. There is no written agreement to continue this support.

Use of Estimates

Trade Accounts Receivable and Concentration Risk

For the six months ended June 30, 2019, one customer made up 100% of the Companys net revenue and three customers made up 94% of the Companys outstanding accounts receivable balance.

For the six months ended June 30, 2018, two customers accounted for 62% and 24% of the Companys net revenue, respectively.

For the year ended December 31, 2018, three customers made up 98.9% of the Companys outstanding accounts receivable balance.

Inventory

Inventory is valued at the lower of cost or market using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of raw materials purchased by the Company and finished goods.

	June 30, 2019		December 31, 2018
Raw materials	$	72,121	$	46,121
Finished goods		27,686		37,573
	$	99,807	$	83,694

During the six months ended June 30, 2019 and 2018, the Company determined $0 and $0, respectively, of inventory should be impaired and written-off to cost of goods sold.

Stock Based Compensation

Per Share Information

The total potential common shares as of June 30, 2019 and 2018, include 50,100,000 of restricted stock units and 14,150,000 of common stock held in escrow, respectively.

New Accounting Pronouncements, Recently Adopted Accounting Pronouncements

Leases

XML 26 R15.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Significant Accounting Policies (Tables)

Schedule of inventory

	June 30, 2019		December 31, 2018
Raw materials	$	72,121	$	46,121
Finished goods		27,686		37,573
	$	99,807	$	83,694

XML 27 R16.htm IDEA: XBRL DOCUMENT

Issuances of Securities (Tables)

6 Months Ended

Jun. 30, 2019

Issuances of Securities (Tables)

Restricted stock units

			Weighted
			Average
			Grant
	Number of		Date Fair
	Units		Value
Total awards outstanding at December 31, 2018		-	$	-
Units granted		50,100,000	$	0.94
Units Exercised/Released		-	$	-
Units Cancelled/Forfeited		-	$	-
Total awards outstanding at June 30, 2019		50,100,000	$	0.94

XML 28 R17.htm IDEA: XBRL DOCUMENT

Liability for Unissued Shares (Tables)

6 Months Ended

Jun. 30, 2019

Liability for Unissued Shares

Schedule of liabilities for unissued shares

	2019		2018
Balance, beginning	$	201,843	$	211,843
Issuance of shares in satisfaction of liability		-		(10,000	)
Balance, ending	$	201,843	$	201,843

XML 29 R18.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Significant Accounting Policies (Details)
Raw materials	$ 72,121	$ 46,121
Finished goods	27,686	37,573
Total inventory	$ 99,807	$ 83,694

XML 30 R19.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Bad debt expense	$ 0	$ 0
Write-off of inventory	$ 0	$ 0
Common stock held in escrow	14,150,000	14,150,000
Restricted stock units	50,100,000	50,100,000
Outstanding accounts receivable [Member] \| Three customers [Member]
Concentration risk, percentage	94.00%		98.90%
Net revenue [Member] \| One customer [Member]
Concentration risk, percentage	100.00%	62.00%
Net revenue [Member] \| Two customers [Member]
Concentration risk, percentage		24.00%

XML 31 R20.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 22, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Apr. 15, 2019	Dec. 31, 2018
Accrued liabilities - related party		$ 55,121		$ 55,121			$ 25,000
Notes payable - related parties							8,121
Accrued compensation		35,000		35,000
Payment of compensation							61,500
Salary		61,500		$ 61,500			180,000
Executive compensation stock bonus package, description				Mr. Beplate shall receive an amount equal to 15% post issuance of the then outstanding shares of the Company's common stock on a fully diluted basis. It was intended that the board approved stock bonus package will be in lieu of the 5% stock bonus that Mr. Beplate is already entitled to in the event of a sale of the Company’s assets or change in control or merger transaction per his services agreement. See “Note 4” regarding the granting of Restricted Stock Unit Agreements (“RSU’s”) to various officers, directors and consultants covering an aggregate of 50,100,000 shares of common stock to be issued upon the satisfaction of certain conditions described in Note 4. Included in the RSU’s are 33,000,000 to Douglas Beplate in lieu of the compensation stock bonus package described above.
Salary							$ 180,000
Repayment of notes payable					$ (10,000)
Proceeds from related party				$ 192,000
Restricted stock units				50,100,000	50,100,000
Interest expense		(156,890)		$ (156,890)
Common stock shares issued			19,838,931		19,838,931
Fair market value				$ 190,000	$ 15,423,500
Two Directors [Member]
Shares issued for services, shares				100,000
Fair market value				$ 190,000
Office Administrator [Member]
Market value per share			$ 1.09		$ 1.09		$ 1.09
Douglas Beplate [Member]
Accrued liabilities - related party		55,121		55,121			$ 86,500
Repayment of notes payable				305,207
Notes payable - related parties		$ 0		0
Officers Compensation				33,000,000
Proceeds from related party				$ 192,000
Convertible loans per share						$ 0.50
Convertible notes per share		$ 0.50		$ 0.50		$ 0.65
Stock price per share	$ 0.90
Restricted stock units				50,100,000
Interest expense	$ 156,890
Converted notes payable and accrued liabilities		$ 205,000		$ 205,000
Unamortized debt discount		$ 0		0
Conversion of stock, amount converted				$ 4,879
Common stock shares issued		410,000		410,000
Travel expenses and consulting				$ 30,000
Douglas Beplate [Member] \| Employment agreement [Member]
Periodic payment term monthly				$ 15,000
Mr. Nate Knight [Member]
Market value per share							$ 1.09

XML 32 R21.htm IDEA: XBRL DOCUMENT

Issuances of Securities (Details)	6 Months Ended
Issuances of Securities (Details)	Jun. 30, 2019 $ / shares shares
Issuances of Securities (Details)
Total awards outstanding begining \| shares
Units granted \| shares	50,100,000
Units Exercised/Released \| shares
Units Cancelled/Forfeited \| shares
Total awards outstanding ending \| shares	50,100,000
Total awards outstanding begining \| $ / shares
Units granted \| $ / shares	0.94
Units Exercised/Released \| $ / shares
Units Cancelled/Forfeited \| $ / shares
Total awards outstanding ending \| $ / shares	$ 0.94

XML 33 R22.htm IDEA: XBRL DOCUMENT

Issuances of Securities (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
Issuances of Securities (Details Narrative) - USD ($)	Jan. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Proceeds from sale of stock				$ 850,200	$ 1,276,481
Fair market value				190,000	$ 15,423,500
Proceeds from sale received				$ 5,000
Common stock shares issued			19,838,931		19,838,931
Issuance of common stock, shares					7,246
Loss on settlement of debt					$ 3,632,500
Shares issued for services, share					850,000
Issuance of shares in satisfaction of liability, shares					5,000
Issuance of shares in satisfaction of liability, amount					$ 62,500
Unrecognized compensation cost				$ 47,094,000
Issuance of shares in satisfaction of liability, shares					5,000
Common stock expensed value				$ 2,343,500
Accrued liabilities - related party		55,121		$ 55,121		$ 25,000
Restricted stock units [Member]
Restricted stock issued replacement				12,000,000
Canceled shares				12,000,000
Office Administrator [Member]
Market value per share			$ 1.09		$ 1.09	$ 1.09
Two Directors [Member]
Shares issued for services, shares				100,000
Fair market value				$ 190,000
Accrued liabilities - related party
CEO [Member]
Shares issued for services, shares				410,000
Accrued liabilities - related party		$ 205,000		$ 205,000
Individuals [Member] \| Unaffiliated [Member]
Shares issued for services, share				50,000
Market value per share		$ 1.09		$ 1.09
Escrow [Member]
Shares issued for services, share				14,150,000	14,150,000
Fair value of common stock		$ 15,423,500		$ 15,423,500
Common stock shares issued and placed in escrow, shares	14,150,000
Escrow [Member] \| Office Administrator [Member]
Common stock shares issued		500,000		500,000
Escrow [Member] \| CFO [Member]
Common stock shares issued		1,600,000		1,600,000
Escrow [Member] \| CEO [Member]
Common stock shares issued		50,000		50,000
Non-Affiliated Investors [Member] \| Private Placement [Member]
Proceeds from sale of stock				$ 200,000
Fair market value				$ 190,000
Sale of stock, shares issued				1,435,769
Proceeds from sale of stock				$ 910,750
Total fair value, shares				200,000
Shares issued for services, shares				400,000
Issuances of Securities [Member]
Loss on settlement of debt					$ (3,632,500)
Issuance of shares in satisfaction of liability, amount				$ 10,000
Conversion of stock, shares					3,500,000
Conversion of stock, amount					$ 172,500
Accrued interest				10,000
Market value for services		$ 674,500		674,500
Share Issuances 2019 [Member] \| CFO [Member]
Proceeds from sale received				$ 20,000,000
Restricted common stock shares				50,100,000
Canceled shares				12,000,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

Litigation (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
Litigation (Details Narrative) - USD ($)	Jun. 30, 2019	Dec. 31, 2017
Lawsuit, description		Complaint was filed with the United States District Court, Southern District of New York by Steven Safran as Plaintiff against the Company and Douglas Beplate, its CEO, as Defendant. This court case was transferred to the United States District Court in Las Vegas, Nevada. Mr. Safran is seeking damages and monies allegedly owed pursuant to an employment agreement and allegedly unpaid loans of $245,824 provided to Defendants. The Company has denied Plaintiff's allegations and intends to vigorously defend said lawsuit.
Shares issued for services, shares		800,000
Maxim Group LLC [Member] \| July 2015 [Member]
Shares issued for services, shares	4,000,000
Shares issued to related party under counterclaim for breach of contract	500,000
Former Chief Executive Officer and Chief Medical Advisor [Member]
Loss contingency damages sought, minimum amount	$ 2,795,000
Loss contingency damages sought, punitive damages	$ 8,280,000
FSR Inc [Member]
Loss contingency damages sought, description	In the Southern District of New York, FSR Inc commenced a lawsuit in 2018 against Korsair Holdings A.G. seeking among other claims for relief, rescission of the transfer of 3,050,000 shares of United Health Products that FSR sold to Korsair in 2011. Third-Party Plaintiff, JEC Consulting Associates, LLC as Liquidator of LeadDog Capital L.P., Intervenor (“Intervenor”) in the above matter, filed a third-party complaint against United Health Products, and Douglas K. Beplate (“Beplate”) alleging among other things that the Company and Mr. Beplate refused to have the Rule 144 restrictive legend removed from the Korsair certificate held by JEC, and concomitantly fraudulently deprive JEC as Liquidator of LeadDog of the ability to sell the Shares in the open market, knowingly, intentionally and directly causing economic harm to LeadDog Capital L.P. Intervenor as Third Party Plaintiff further alleges that the Company and Mr. Beplate as Third-Party Defendants are not only monetarily liable to Third-Party Plaintiff for compensatory damages of $2,500,000 but should be made to pay exemplary damages in an amount determined by the Court, but not less than an equal amount - $2,500,000. Third-Party Plaintiff demands judgment for the above referenced amounts and for the Court to also declare that the 3,050,000 shares are free trading; that Third-Party Plaintiff’s rights to 2.5 million of the Shares are superior to the claims of Plaintiff FSR; that Plaintiff FSR has no claim to 2.5 million of the 3,050,000 Shares reflected by the Korsair certificate

XML 35 R24.htm IDEA: XBRL DOCUMENT

Liability for Unissued Shares (Details) - USD ($)	6 Months Ended	12 Months Ended
Liability for Unissued Shares (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Other Notes Payable Details Abstract
Balance, beginning	$ 201,843	$ 211,843
Issuance of shares in satisfaction of liability		(10,000)
Balance, ending	$ 201,843	$ 201,843

XML 36 R25.htm IDEA: XBRL DOCUMENT

Liability for Unissued Shares (Details Narrative) - shares	Jun. 30, 2019	Dec. 31, 2018
Liability for Unissued Shares (Details Narrative)
Shares granted but unissued	2,414,059	2,414,059

EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

Issuances of Securities (Details)	6 Months Ended
Issuances of Securities (Details)	Jun. 30, 2019 $ / shares shares
Issuances of Securities (Details)
Total awards outstanding begining \| shares
Units granted \| shares	50,100,000
Units Exercised/Released \| shares
Units Cancelled/Forfeited \| shares
Total awards outstanding ending \| shares	50,100,000
Total awards outstanding begining \| $ / shares
Units granted \| $ / shares	0.94
Units Exercised/Released \| $ / shares
Units Cancelled/Forfeited \| $ / shares
Total awards outstanding ending \| $ / shares	$ 0.94

					Additional
	Common Stock				Paid-in			Accumulated
	Shares		Amount		Capital			Deficit			Total

Balance at December 31, 2017		164,969,663	$	164,969	$	13,304,617		$	(13,730,851	)	$	(261,265	)

Issuance of shares for notes payable and accrued interest		3,500,000		3,500		3,811,500			-			3,815,000

Issuance of common stock for services		50,000		50		54,450			-			54,500

Sale of common stock		440,725		441		275,660			-			276,101

Shares issued for liability of unissued shares		62,500		63		4,937			-			5,000

Shares held in escrow		14,150,000		14,150		(14,150	)		-			-

Net Loss		-		-		-			(3,990,041	)		(3,990,041	)

Balance at March 31, 2018		183,172,888	$	183,173	$	17,437,014		$	(17,720,892	)	$	(100,705	)

Issuance of common stock for services		800,000		800		619,200			-			620,000

Sale of common stock		698,697		699		481,401			-			482,100

Shares issued for liability of unissued shares		137,059		137		91,863			-			92,000

Net Loss		-		-		-			(914,545	)		(914,545	)

Balance at June 30, 2018		184,808,644	$	184,809	$	18,629,478		$	(18,635,437	)	$	178,850

	Common Stock						Additional Paid-in		Accumulated
	Shares			Amount			Capital		Deficit			Total
Balance at December 31, 2018		185,943,138		$	185,943		$	19,198,343	$	(19,736,986	)	$	(352,700	)

Vesting of shares held in escrow		-			-			2,343,500		-			2,343,500

Issuance of common stock for services		400,000			400			379,600		-			380,000

Sale of common stock		150,000			150			74,850		-			75,000

Cancellation of escrow shares		(12,000,000	)		(12,000	)		12,000		-			-

Net Loss		-			-			-		(2,985,897	)		(2,985,897	)

Balance at March 31, 2019		174,493,138		$	174,493		$	22,008,293	$	(22,721,883	)	$	(540,097	)

Sale of common stock		1,685,769			1,686			1,034,064		-			1,035,750

Issuance of shares for notes payable and accrued liabilities – related party		410,000			410			204,590		-			205,000

Beneficial conversion feature		-			-			156,890		-			156,890

Net Loss		-			-			-		(713,000	)		(713,000	)

Balance at June 30, 2019		176,588,907		$	176,589		$	23,403,837	$	(23,435,883	)	$	144,543

	·	In March 2018, the Company obtained Class III and CE mark approval for HemoStyp in the European Economic Area (EEA). The EEA comprises the 28 European Union members and certain other countries. Accordingly, HemoStyp was approved for use in internal surgical procedures in more than 30 countries. This approval expired in August of 2018 and a new application will be prepared in conjunction with the new CE standards for Class III following the expected FDA Class III approval. The EEA approval was granted following the provision of all required documentation to the relevant regulatory agencies. The CE marking– CE is an acronym for the French term "Conformité Européenne"– certifies that a product has met EEA health, safety, and environmental requirements, which ensure consumer safety. Manufacturers in the EEA and abroad must meet CE marking requirements where applicable to market their products in Europe. A manufacturer who has gone through the conformity assessment process may affix the CE mark to its product. With the CE marking, the product may be marketed throughout the EEA and certain other countries, with a combined population exceeding 517 million and a GDP greater than $17 trillion.

	·	In July 2018, the Company announced that it has been accepted as a Walmart.com supplier and offers two HemoStyp wound care products for online retail sale. Hemostrips® Hemostatic Bandages and Boo-boo Strip Hemostatic Bandages.

	·	On August 8, 2018, the Company announced that its protocol submission for human testing had been reviewed by the FDA in furtherance of our efforts to achieve Class III approval for the product in the U.S. This FDA review was provided to the Institutional Review Board (IRB) for protocol and hospital site approval. UHP started the human trial study in November. The IRB is a committee that is independent of the FDA, and that is formally designated to approve, monitor, and review biomedical and behavioral research involving humans. The purpose of the IRB is to assure that appropriate steps are taken to protect the rights and welfare of humans participating as subjects in a research study. The Company’s human trial protocol calls for the application of HemoStyp in abdominal, cardiovascular thoracic and vascular surgical procedures to control bleeding sites. Prior to finalizing its human trial protocol, we submitted a Q-Sub – a request for FDA review — to the FDA, in conjunction with its previously filed Class III PMA submission application.